AAT DEFICIENCY

Products Affected
- Aralast NP intravenous recon soln 1,000 mg
- Glassia
- Prolastin-C intravenous recon soln
- Zemaira

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis of severe congenital A1-PI deficiency who have clinically evident emphysema, weight, A1-PI phenotype, A1-PI baseline level</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by a pulmonologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>6 months for initiation, 1 year for continuation</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## ADAPALENE

### Products Affected
- adapalene topical cream
- adapalene topical gel 0.1%
- adapalene topical swab

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>Not approved when used to treat photo aging.</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, previous treatments, and response therapy</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 year</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Must have failure, intolerance, or contraindication to tretinoin</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# ADEMPAS

## Products Affected
- Adempas

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Confirmation of diagnosis, documentation of response to any prior therapies</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by pulmonologist or cardiologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 months initial, 1 year continuation</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>For WHO Group 1 diagnosis, patient must have a history of taking or contraindication to sildenafil (Revatio).</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
### AFINITOR

**Products Affected**
- Afinitor
- Afinitor Disperz

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>DIAGNOSIS, PRIOR THERAPIES, AND TREATMENT RESPONSE</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>PRESCRIPTION MUST BE WRITTEN BY ONCOLOGIST OR NEUROLOGIST</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Formulary ID 20495, V#9
AIMOVIG

Products Affected
- Aimovig Autoinjector

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, other therapies tried, and outcome. Member has been evaluated for and does not have medication overuse headache.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>18 years of age or older</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Must be prescribed by or in consultation with a neurologist or pain specialist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 year</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Patient must have an inadequate response, contraindication, or intolerance to two different chronic migraine prevention drugs. The two prerequisite drugs must be from different classes such as anticonvulsants (topiramate/valproate), beta blockers (propranolol, metoprolol), and antidepressants (nortriptyline/venlafaxine).</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# ALK POSITIVE TYROSINE KINASE INHIBITORS

## Products Affected
- Alecensa
- Xalkori
- Zykadia oral tablet

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, other treatments tried and outcome</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescribed by an oncologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medicallyaccepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
ALUNBRIG

Products Affected
- Alunbrig

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical</td>
<td>Non-small cell lung cancer (NSCLC): Diagnosis of metastatic NSCLC. Patient has an anaplastic lymphoma kinase (ALK)-positive tumor as detected with an FDA-approved test or Clinical Laboratory Improvement Amendments-approved facility. Trial and failure or intolerance to Xalkori (crizotinib).</td>
</tr>
<tr>
<td>Information</td>
<td></td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescribed by or in consultation with an oncologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Approve for continuation of prior therapy.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
**AMIFAMPRIDINE**

### Products Affected
- Firdapse
- Ruzurgi

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Must have a documented diagnosis of Lambert-Eaton with electrodiagnostic studies including repetitive nerve stimulation and anti-P/Q-type voltage-gated calcium channel (VGCC) antibody testing to confirm the diagnosis.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by a neurologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 year</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
### AMPYRA

**Products Affected**
- Ampyra

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Exclusion Criteria</strong></td>
<td>NOT A COVERED BENEFIT IN PATIENTS WITH SEIZURE DISORDER OR A CREATININE CLEARANCE LESS THAN 50 ML/MIN</td>
</tr>
<tr>
<td><strong>Required Medical Information</strong></td>
<td>EXPANDED DISABILITY SCALE SCORE, BASELINE AND FOLLOW-UP 25 FOOT WALK TEST, CREATININE CLEARANCE</td>
</tr>
<tr>
<td><strong>Age Restrictions</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Prescriber Restrictions</strong></td>
<td>PRESCRIPTION MUST BE WRITTEN BY A NEUROLOGIST</td>
</tr>
<tr>
<td><strong>Coverage Duration</strong></td>
<td>3 MONTHS INITIAL, 1 YEAR CONTINUATION</td>
</tr>
<tr>
<td><strong>Other Criteria</strong></td>
<td>PATIENT MUST SHOW AN IMPROVEMENT IN WALKING SPEED TO CONTINUE TREATMENT</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td><strong>Off-Label Uses</strong></td>
<td>N/A</td>
</tr>
</tbody>
</table>
# ANTIDEPRESSANTS

## Products Affected
- Drizalma Sprinkle
- Fetzima
- Trintellix
- Viibryd oral tablet
- Viibryd oral tablets, dose pack 10 mg (7)-20 mg (23)

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>DIAGNOSIS, PRIOR THERAPIES TRIED AND FAILED</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>MUST SEE CONTRAINDICATION TO OR FAILURE OF 2 DIFFERENT CLASSES OF GENERIC ANTIDEPRESSANTS INCLUDING SSRIS, SNRIS, TCAS, NOREPINEPHRINE-DOPAMINE REUPTAKE INHIBITORS, OR NORADRENERGIC AND SPECIFIC SEROTONERGIC ANTIDEPRESSANTS. EXAMPLES INCLUDE: SERTRALINE, CITALOPRAM, ESCITALOPRAM, FLUOXETINE, PAROXETINE, VENLAFAXINE, DULOXETINE, BUPROPION, AMITRIPTYLINE, DOXEPIN, ETC.</td>
</tr>
</tbody>
</table>

## Indications
All Medically-accepted Indications.

## Off-Label Uses
N/A
ANTIPSYCHOTICS

Products Affected
- Abilify Maintena
- Aristada
- Aristada Initio
- chlorpromazine 25mg/mL ampule
- Fanapt
- Invega Sustenna
- Invega Trinza
- Latuda
- Rexulti
- Saphris
- Versacloz
- Vraylar

PA Criteria | Criteria Details
--- | ---
Exclusion Criteria | N/A
Required Medical Information | FOR BIPOLAR DISORDER OR SCHIZOPHRENIA, DOCUMENTATION OF DIAGNOSIS, TREATMENT FAILURE WITH TWO ATYPICAL ANTIPSYCHOTICS (ZIPRASIDONE, RISPERIDONE, QUETIAPINE, OLANZAPINE, CLOzapine), OR RATIONALE AS TO WHY ALTERNATIVES ARE NOT SUITABLE
Age Restrictions | N/A
Prescriber Restrictions | N/A
Coverage Duration | 2 years
Other Criteria | N/A
Indications | All Medically-accepted Indications.
Off-Label Uses | N/A
# APOKYN

## Products Affected
- APOKYN

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, prior treatments, and outcome</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescribed by neurologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 year</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Treatment failure or inotlernace to ropinirole and pramipexole.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# ARCALYST

## Products Affected
- Arcalyst

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>N/A</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>12 YEARS AND OLDER</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 YEAR AT A TIME</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## BALVERSA

### Products Affected
- Balversa

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, prior treatments, and outcome</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by oncologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
### BENLYSTA

**Products Affected**
- Benlysta subcutaneous syringe

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>Severe active lupus nephritis, active central nervous, use in combination with other biologics</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, autoantibody testing, prior treatments including response, and SLEDAI score.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>must be 18 and older</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by a rheumatologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>6 months</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Failed to demonstrate adequate response to TWO standard therapies at recommended doses: corticosteroids, antimalarials, NSAIDs, and/or immunosuppressants. SLEDAI score greater than 8.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
BOSULIF

Products Affected
• Bosulif oral tablet 100 mg, 400 mg, 500 mg

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, prior therapy used, result of prior therapy. If continuation, prior</td>
</tr>
<tr>
<td></td>
<td>response to bosutinib. CBC and LFT lab test results are needed for continuation</td>
</tr>
<tr>
<td></td>
<td>treatment.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by an oncologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
BRAFTOVI

Products Affected
- Braftovi oral capsule

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to treatment.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by an oncologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## CABOMETYX

### Products Affected
- Cabometyx

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Renal cell carcinoma (RCC): Diagnosis of RCC. RCC is advanced. History of failure, contraindication, or intolerance to at least one prior anti-angiogenic therapy [e.g., Nexavar (sorafenib), Sutent (sunitinib)].</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescribed by or in consultation with an oncologist.</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
CALQUENCE

Products Affected
- Calquence

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>NA</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Documentation of diagnosis, previous treatments, and response to treatment.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescribed by oncology</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Formulary ID 20495, V#9
**CAPRELSA**

**Products Affected**
- Caprelsa oral tablet 100 mg, 300 mg

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Exclusion Criteria</strong></td>
<td><strong>HISTORY OF CONGENITAL LONG QT SYNDROME</strong></td>
</tr>
<tr>
<td><strong>Required Medical Information</strong></td>
<td><strong>DIAGNOSIS, PRIOR THERAPIES, TREATMENT RESPONSE</strong></td>
</tr>
<tr>
<td><strong>Age Restrictions</strong></td>
<td><strong>18 YEARS AND OLDER</strong></td>
</tr>
<tr>
<td><strong>Prescriber Restrictions</strong></td>
<td><strong>PRESCRIPTION MUST BE WRITTEN BY ONCOLOGIST</strong></td>
</tr>
<tr>
<td><strong>Coverage Duration</strong></td>
<td><strong>2 years</strong></td>
</tr>
<tr>
<td><strong>Other Criteria</strong></td>
<td><strong>ECG, ELECTROLYTE(K,Mg,Ca), AND TSH MONITORING AT BASELINE, 2-4 WEEKS AND 8-12 WEEKS AFTER STARTING TREATMENT AND EVERY 3 MONTHS THEREAFTER</strong></td>
</tr>
<tr>
<td><strong>Indications</strong></td>
<td><strong>All Medically-accepted Indications.</strong></td>
</tr>
<tr>
<td><strong>Off-Label Uses</strong></td>
<td><strong>N/A</strong></td>
</tr>
</tbody>
</table>
## CINQAIR

### Products Affected
- Cinqair

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Covered Uses</td>
<td>All medically accepted indications not otherwise excluded from Part D.</td>
</tr>
<tr>
<td>Exclusion Criteria</td>
<td>Administration of reslizumab requires a specialized care setting and requires an experienced clinician prepared to manage anaphylaxis will not be approved for self-administration</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Allergen test, baseline FEV1, FEV1 following bronchodilator, asthma medical history (including medications, emergency department visits, and hospitalizations), baseline eosinophil count</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Pulmonology or Immunologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 year</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Patient must be diagnosed with severe asthma, currently receiving inhaled and/or oral corticosteroid treatment, have a baseline eosinophil count of 400/mcL, have a contraindication, intolerance or failure of Nucala.</td>
</tr>
</tbody>
</table>
# COMETRIQ

## Products Affected
- Cometriq

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, prior therapy used, result of prior therapy.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by an oncologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
**COPIKTRA**

**Products Affected**
- Copiktra

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical</td>
<td>Diagnosis, prior therapy used, result of prior therapy. If continuation, prior</td>
</tr>
<tr>
<td>Information</td>
<td>response to treatment.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by an oncologist or hematologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
CORLANOR

Products Affected
- Corlanor

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>For heart failure in adult patients, only: ejection fraction less than or equal to 35% AND heart rate greater than 70 beats per minute AND in sinus rhythm AND on maximally tolerated beta-blocker OR has contraindication to beta-blocker (i.e., allergy, severe COPD limiting beta blocker usage).</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescribed by a cardiologist.</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>12 months</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## COSENTYX

### Products Affected
- Cosentyx (2 Syringes)
- Cosentyx Pen (2 Pens)

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, prior therapy used, result of prior therapy</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Must be prescribed by a Rheumatologist or Dermatologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 months for initiation, 1 year for continuation</td>
</tr>
</tbody>
</table>
| Other Criteria               | For arthritis conditions, must have a trial of or contraindication to one non-
                               | biologic DMARD (including but not limited to methotrexate, hydroxychloroquine,  |
                               | sulfasalazine, azathioprine). For diagnosis of plaque psoriasis, must have a trial  |
                               | of or contraindication to cyclosporine or methotrexate                           |
| Indications                  | All Medically-accepted Indications.                                              |
| Off-Label Uses               | N/A                                                                              |
# COTELLCIC

## Products Affected
- Cotellc

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, other therapies tried and/or failed, and treatment response.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescribed by an oncologist.</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# DALIRESP

## Products Affected
- Daliresp

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Chronic Obstructive Pulmonary Disease (COPD), medications tried.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>COPD, approve in patients who meet all of the following conditions: Patients has severe COPD or very severe COPD, AND Patient has a history of exacerbations, AND Patient has tried a medication from two of the three following drug categories: long-acting beta2-agonist (LABA) [eg, salmeterol, indacaterol], long-acting muscarinic antagonist (LAMA) [eg, tiotropium], inhaled corticosteroid (eg, fluticasone).</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## DAURISMO

### Products Affected
- Daurismo

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical</td>
<td>Diagnosis, prior therapies, and result of prior therapy.</td>
</tr>
<tr>
<td>Information</td>
<td></td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by an oncologist or hematologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# DEMSER

**Products Affected**
- Demser

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis and whether the patient is a candidate for surgery</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 months</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
DICLOFENAC GEL 3%

Products Affected

- diclofenac sodium topical gel 3%

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis and any prior treatments.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by a Dermatologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 months</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# DOPELET

## Products Affected
- Doptelet (10 tab pack)
- Doptelet (15 tab pack)
- Doptelet (30 tab pack)

## PA Criteria

<table>
<thead>
<tr>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
</tr>
<tr>
<td>Required Medical Information</td>
</tr>
<tr>
<td>Age Restrictions</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
</tr>
<tr>
<td>Coverage Duration</td>
</tr>
<tr>
<td>Other Criteria</td>
</tr>
<tr>
<td>Indications</td>
</tr>
<tr>
<td>Off-Label Uses</td>
</tr>
</tbody>
</table>

Formulary ID 20495, V#9
### DRONABINOL

#### Products Affected
- dronabinol

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>Not covered for the treatment of pain</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, previous treatments, and the outcome</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 year</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>For cancer related weight loss must have a treatment failure or intolerance to megestrol.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
Prior Authorization Criteria
Health Alliance Plan 2020
Date Effective: 02/01/2020

EGRIFTA

Products Affected
• Egrifta subcutaneous recon soln 1 mg

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Covered Uses</strong></td>
<td>All medically accepted indications not otherwise excluded from Part D.</td>
</tr>
<tr>
<td><strong>Exclusion Criteria</strong></td>
<td>ONLY APPROVED FOR PATIENTS WITH HIV ASSOCIATED LIPODYSTROPHY. NOT INDICATED FOR WEIGHT MANAGEMENT.</td>
</tr>
<tr>
<td><strong>Required Medical Information</strong></td>
<td>DIAGNOSIS, BASELINE WAIST CIRCUMFERENCE, BASELINE IGF-1 FASTING PLASMA GLUCOSE, AND BASELINE HGAIC. MONITORING EVERY 6 MONTHS OF PARAMETERS LISTED ABOVE. MUST NOT HAVE AN ACTIVE MALIGNANCY</td>
</tr>
<tr>
<td><strong>Age Restrictions</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Prescriber Restrictions</strong></td>
<td>PRESCRIPTION MUST BE WRITTEN BY AN INFECTIOUS DISEASE SPECIALIST OR ENDOCRINOLOGIST</td>
</tr>
<tr>
<td><strong>Coverage Duration</strong></td>
<td>3 MONTHS</td>
</tr>
<tr>
<td><strong>Other Criteria</strong></td>
<td>N/A</td>
</tr>
</tbody>
</table>
**EMEND**

**Products Affected**
- aprepitant

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Exclusion Criteria</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Required Medical Information</strong></td>
<td>For use with highly and moderately-emetogenic chemotherapy, provide the chemotherapy regimen including drug, dose, and frequency. Ondansetron is preferred for post-operative nausea/vomiting (PONV) prophylaxis. When aprepitant is used for PONV prophylaxis, provide rationale as to why ondansetron is not a suitable alternative.</td>
</tr>
<tr>
<td><strong>Age Restrictions</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Prescriber Restrictions</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Coverage Duration</strong></td>
<td>6 months</td>
</tr>
<tr>
<td><strong>Other Criteria</strong></td>
<td>Drug will also be reviewed for coverage under part B versus part D.</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td><strong>Off-Label Uses</strong></td>
<td>N/A</td>
</tr>
</tbody>
</table>
ENBREL

Products Affected
- Enbrel
- Enbrel SureClick

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>Concurrent use with biologic therapy or targeted synthetic DMARD</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, concurrent medications, previous therapies tried.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>RA/AS/JIA/JRA, prescribed by or in consult w/ rheumatologist. PsA, prescribed by or in consultation w/ dermatologist. PP, prescribed by or in consult w/ dermatologist, GVHD, prescribed by or in consult w/ oncologist, hematologist, or physician affiliated w/ transplant center. Behcet's disease, prescribed by or in consult w/ rheumatologist, dermatologist, ophthalmologist, gastroenterologist, or neurologist. Uveitis, prescribed by or in consult w/ ophthalmologist.</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>FDA approved indications - 3 months initial, 3 years cont, others 12 months.</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>RA initial, patient has tried one conventional synthetic DMARD for at least 3 months (note: patients who have already had a 3-month trial of a biologic for RA are not required to step back and try a conventional synthetic DMARD). JIA/JRA, approve if the pt has aggressive disease, as determined by the prescriber, or the pt has tried one other agent for this condition (eg, MTX, sulfasalazine, leflunomide, NSAID, biologic DMARD or the pt will be started on Enbrel concurrently with MTX, sulfasalazine, or leflunomide or the pt has an absolute contraindication to MTX (eg, pregnancy, breast feeding, alcoholic liver disease, immunodeficiency syndrome, blood dyscrasias), sulfasalazine, or leflunomide. Plaque psoriasis (PP) initial approve if the patient meets one of the following conditions: 1) patient has tried at least one traditional systemic agent for at least 3 months for plaque psoriasis, unless intolerant (eg, MTX, cyclosporine, Soriatane, oral methoxsalen plus PUVA, (note: pts who have already tried a biologic for psoriasis are not required to step back and try a traditional agent first)</td>
</tr>
</tbody>
</table>
## Prior Authorization Criteria

**Health Alliance Plan 2020**  
**Date Effective:** 02/01/2020

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>OR 2) the patient has a contraindication to one oral agent for psoriasis such as MTX. GVHD. Tried or currently is receiving with etanercept 1 conventional GVHD tx (high-dose systemic corticosteroid, CSA, tacrolimus, MM, thalidomide, antithymocyte globulin, etc.). Behcet's. Has tried at least 1 conventional tx (eg, systemic corticosteroid, immunosuppressant, interferon alfa, MM, etc) or adalimumab or infliximab. Uveitis-tried one of the following: periocular, intraocular, or systemic corticosteroid, immunosuppressives, Humira or an infliximab product. RA/AS/JIA/PP/PsA Cont - must have a response to tx according to the prescriber. Behcet's, GVHD, Uveitis Cont-if the patient has had a response to tx according to the prescriber. Clinical criteria incorporated into the Enbrel 25 mg quantity limit edit, approve additional quantity (to allow for 50 mg twice weekly dosing) if one of the following is met: 1) Patient has plaque psoriasis, OR 2) Patient has RA/JIA/PsA/AS and is started and stabilized on 50 mg twice weekly dosing, OR 3) Patient has RA and the dose is being increased to 50 mg twice weekly and patient has taken MTX in combination with Enbrel 50 mg once weekly for at least 2 months, unless MTX is contraindicated or intolerant, OR 4) Patient has JIA/PsA/AS and the dose is being increased to 50 mg twice weekly after taking 50 mg once weekly for at least 2 months.</td>
<td></td>
</tr>
</tbody>
</table>

### Indications

- All Medically-accepted Indications.

### Off-Label Uses

- N/A
### EPILOIDELEX

#### Products Affected
- Epidiolex

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to treatment.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by or in consultation with a neurologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>For Lennox-Gastaut Syndrome: treatment failure or intolerance to valproate and lamotrigine. For Dravet Syndrome: treatment failure or intolerance to: valproate and topiramate.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# ERIVEDGE

## Products Affected
- Erivedge

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Exclusion Criteria</strong></td>
<td>PATIENTS WHO ARE CANDIDATES FOR SURGERY OR RADIATION</td>
</tr>
<tr>
<td><strong>Required Medical Information</strong></td>
<td>DIAGNOSIS, PRIOR TREATMENTS, RESPONSE TO THERAPY</td>
</tr>
<tr>
<td><strong>Age Restrictions</strong></td>
<td>18 YEARS OF AGE AND OLDER</td>
</tr>
<tr>
<td><strong>Prescriber Restrictions</strong></td>
<td>PRESCRIPTION MUST BE WRITTEN BY A ONCOLOGIST OR DERMATOLOGIST</td>
</tr>
<tr>
<td><strong>Coverage Duration</strong></td>
<td>2 years</td>
</tr>
<tr>
<td><strong>Other Criteria</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td><strong>Off-Label Uses</strong></td>
<td>N/A</td>
</tr>
</tbody>
</table>
## ERLEADA

### Products Affected
- Erleada

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical</td>
<td>Diagnosis, other therapies tried and outcome, fall risk assessment, and seizure</td>
</tr>
<tr>
<td>Information</td>
<td>history (if any)</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Must be prescribed by an oncologist or urologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 year</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## ERYTHROPOIESIS STIMULATING AGENTS

### Products Affected
- Aranesp (in polysorbate) injection solution 100 mcg/mL, 200 mcg/mL, 25 mcg/mL, 300 mcg/mL, 40 mcg/mL, 60 mcg/mL
- Aranesp (in polysorbate) injection syringe
- Epogen injection solution 2,000 unit/mL, 20,000 unit/2 mL, 20,000 unit/mL, 3,000 unit/mL, 4,000 unit/mL
- Procrit injection solution 10,000 unit/mL, 2,000 unit/mL, 20,000 unit/mL, 3,000 unit/mL, 4,000 unit/mL, 40,000 unit/mL

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Exclusion Criteria</strong></td>
<td>Uncontrolled hypertension. Pure red cell aplasia that begins after ESA treatment.</td>
</tr>
<tr>
<td><strong>Required Medical Information</strong></td>
<td>Pre-treatment hemoglobin level less than 10 g/dL AND Patient has adequate iron stores prior to initiation of therapy defined as ferritin more than 100 mcg/L or serum transferrin saturation greater than 20% AND other causes of anemia such as iron deficiency, folate deficiency or B12 deficiency, hemolysis, gastrointestinal bleeding, other active or occult bleeding, or underlying hematologic disease (such as sickle cell anemia, thalassemia, and porphyria) have been ruled out.</td>
</tr>
<tr>
<td><strong>Age Restrictions</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Prescriber Restrictions</strong></td>
<td>CKD - prescribed by a nephrologist or hematologist. Non-myeloid malignancies - prescribed by an oncologist/hematologist. Surgery - Prescribed by a surgeon. HIV - Prescribed by an infectious disease specialist.</td>
</tr>
<tr>
<td><strong>Coverage Duration</strong></td>
<td>Initial: 3 months. Renewal: CKD-12 months, Non-myeloid cancers, HIV-4 months. Surgery-3 months</td>
</tr>
<tr>
<td><strong>Other Criteria</strong></td>
<td>For renewal of CKD, for dialysis patients: Hb less than 11 g/dL or physician will decrease or interrupt dose and for non-dialysis patients: Hb less than 10 g/dL or physician will decrease or interrupt dose. For renewal of non-myeloid malignancies: Concurrent myelosuppressive chemotherapy and Hb is 12g/dL or less and there is measurable response after eight weeks (defined as an increase in Hb 1 g/dL or more or a reduction in red blood cell transfusion requirements). For renewal of zidovudine-treated HIV, Hb is 12g/dL or less AND Zidovudine dose remains 4,200 mg/week or less and there is a measurable response after eight weeks (defined as an increase in Hb 1 g/dL or more or a reduction in red blood cell transfusion requirements).</td>
</tr>
</tbody>
</table>

Formulary ID 20495, V#9
<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>in Hb or a reduction in RBC transfusion requirements or documented dose escalation [up to max of 300 units/kg/dose]</td>
</tr>
</tbody>
</table>

**Indications**

All Medically-accepted Indications.

**Off-Label Uses**

N/A
Prior Authorization Criteria  
Health Alliance Plan 2020  
Date Effective: 02/01/2020

# EXJADE

## Products Affected
- deferasirox oral tablet, dispersible  
- Exjade

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Serum ferritin, CrCl, serum transaminases and bilirubin, baseline auditory and ophthalmic examinations. For Non-Transfusion-Dependent Thalassemia Syndromes: liver iron concentration (LIC) by liver biopsy or by an FDA-cleared or approved method for identifying patients for treatment with deferasirox therapy. Dose verification</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 months</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>For chronic transfusional iron overload due to blood transfusion: serum ferritin consistently greater than 1000 mcg/L. For NON-transfusion dependent thalassemia syndrome and chronic iron overload a LIC (liver iron concentration) of at least 5 mg Fe/g dry weight and a serum ferritin greater than 300 mcg/L on at least 2 measurements 1 month apart. For patients continuation: current LIC is greater than 3 mg per gram of dry weight or Exjade (deferasirox) will be withheld until the LIC reaches above 5 mg per gram of dry weight.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
FARYDAK

Products Affected
- Farydak

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical</td>
<td>Diagnosis, other therapies tried and/or failed</td>
</tr>
<tr>
<td>Information</td>
<td></td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by an oncologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# FASENRA

## Products Affected
- Fasenra
- Fasenra Pen

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Allergen test, baseline FEV1, FEV1 following bronchodilator, asthma medical history (including medications, emergency department visits, and hospitalizations), baseline eosinophil count</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Must be prescribed by a Pulmonologist or Immunologist or Allergist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>Initiation: 3 months, continuation 1 year</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Patient must be diagnosed with severe asthma, currently receiving inhaled and/or oral corticosteroid treatment, AND have a baseline eosinophil count of 150 cells/mcL or greater within previous 12 months.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# FERRIPROX

## Products Affected
- Ferriprox oral tablet

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, length of therapy, serum ferritin concentrations and dose/weight verification, &amp; CBC</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 months</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Must have a contraindication to, an inadequate response, or has been intolerant to, or experienced clinically significant adverse effects to Exjade, such as evidence of cardiac iron overload or iron-induced cardiac dysfunction with Exjade. For continuation patient must have a 20% or greater reduction in serum ferritin with an adequate dose and duration of therapy.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
**FULYZAQ**

**Products Affected**
- Mytesi

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Exclusion Criteria</strong></td>
<td>Use when infectious diarrhea has not been ruled out</td>
</tr>
<tr>
<td><strong>Required Medical Information</strong></td>
<td>Diagnosis, use of antiretroviral therapy</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 months</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Infectious diarrhea needs to be ruled out prior to initiating treatment. Patient must have a history of using at least two prior treatments for diarrhea, including bismuth subsalicylate, kaolin, loperamide, or diphenoxylate/atropine.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
Prior Authorization Criteria
Health Alliance Plan 2020
Date Effective: 02/01/2020

FYCOMPA

Products Affected
- Fycompa oral suspension
- Fycompa oral tablet

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical</td>
<td>Diagnosis, other therapies tried, response to prior</td>
</tr>
<tr>
<td>Information</td>
<td>therapy</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be prescribed by neurologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Monitor at initiation and after dose increases for</td>
</tr>
<tr>
<td></td>
<td>serious psychiatric and/or behavioral reactions.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## GALAFOLD

### Products Affected
- Galafold

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>Not covered in combination with Fabrazyme</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Confirmed diagnosis of Fabry disease and baseline renal function assessment</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by a specialist in genetic disorders, or nephrologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>6 months for initiation, 1 year for continuation</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# GATTEX

## Products Affected
- Gattex 30-Vial

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Exclusion Criteria</strong></td>
<td>Therapy should be discontinued in cases of intestinal malignancy.</td>
</tr>
<tr>
<td><strong>Required Medical Information</strong></td>
<td>Diagnosis, other therapies tried and/or failed.</td>
</tr>
<tr>
<td><strong>Age Restrictions</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Prescriber Restrictions</strong></td>
<td>Prescription must be written by a gastroenterologist</td>
</tr>
<tr>
<td><strong>Coverage Duration</strong></td>
<td>3 months for initiation, 6 months for continuation</td>
</tr>
<tr>
<td><strong>Other Criteria</strong></td>
<td>A colonoscopy of the entire colon with removal of polyps must be done before initiating therapy, medical records documenting this procedure must be submitted.</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td><strong>Off-Label Uses</strong></td>
<td>N/A</td>
</tr>
</tbody>
</table>
# GAUCHER'S DISEASE TREATMENT

**Products Affected**
- Cerdelga
- miglustat
- Zavesca

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>NOT APPROVED FOR TYPE II OR TYPE III GAUCHER'S DISEASE</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>DIAGNOSIS, WEIGHT. FOR MIGLUSTAT: RATIONALE AS TO WHY ERT IS NOT APPROPRIATE</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>PRESCRIPTION MUST BE WRITTEN BY GENETICIST, HEMOTOLOGIST, OR METABOLIC SPECIALIST</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 YEAR</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>USE OF MIGLUSTAT IS RESERVED FOR THOSE WHOM ENZYME REPLACEMENT THERAPY IS NOT AN OPTION</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## GILOTRIF

### Products Affected
- Gilotrif

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical</td>
<td>Diagnosis, previous therapies tried and/or failed</td>
</tr>
<tr>
<td>Information</td>
<td></td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by oncologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## GLEEVEC

### Products Affected
- imatinib

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>DIAGNOSIS, PRIOR THERAPIES, AND TREATMENT RESPONSE</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>PRESCRIPTION MUST BE WRITTEN BY ONCOLOGIST</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>GENETIC, HEMATOLOGIC, AND CYTOGENIC TESTS ARE REQUIRED BASED ON THE SPECIFIC INDICATION TO ASSESS APPROPRIATE USE AND ADEQUATE RESPONSE TO THERAPY</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# GRALISE

## Products Affected
- Gralise
- Gralise 30-Day Starter Pack

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical</td>
<td>Diagnosis, previous treatments including dosage, outcome of previous treatment</td>
</tr>
<tr>
<td>Information</td>
<td></td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 year</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Must have a documented intolerance, contraindication to, or failure of gabapentin titrated to maximum tolerated dosage or rationale as to why gabapentin cannot be used.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## GROWTH HORMONE

### Products Affected
- Norditropin FlexPro
- Nutropin AQ Nuspin

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>PRESENCE OF CONTRAINDICATIONS TO THERAPY</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>DIAGNOSIS, HEIGHT AND WEIGHT, HISTORY OF GROWTH MEASUREMENT. REPLACEMENT THERAPY IN PATIENTS WITH GROWTH HORMONE DEFICIENCY WITH DIAGNOSIS CONFIRMED BY APPROPRIATE GROWTH HORMONE STIMULATION TESTING</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>PRESCRIPTION MUST BE WRITTEN BY ENDOCRINOLOGIST OR NEPHROLOGIST</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 MONTHS FOR INITIATION, 1 YEAR FOR CONTINUATION</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
HEPATITIS B

Products Affected
- Baraclude oral solution
- entecavir

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>TREATMENT CONSIDERATION IS BASED ON HBEAG, HBV DNA QUANTITY, AND ALT LEVEL</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>PRESCRIPTION MUST BE WRITTEN BY A GASTROENTEROLOGIST, HEPATOLOGIST, OR INFECTIOUS DISEASE SPECIALIST</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 YEAR</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
HEPATITIS C TREATMENT

Products Affected
- Mavyret
- Zepatier

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>PATIENT WEIGHT, GENOTYPE, HCV-RNA, LEVEL OF FIBROSIS, TREATMENT HISTORY</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>PRESCRIPTION MUST BE WRITTEN BY GASTROENTEROLOGIST, HEPATOLOGIST, OR INFECTIOUS DISEASE SPECIALIST</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>8 - 24 WEEKS. TREATMENT WILL BE APPROVED CONSISTENT WITH CURRENT AASLD-IDSA GUIDANCE.</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
HEREDITARY ANGIOEDEMA

Products Affected
- Cinryze
- Haegarda
- icatibant
- Takhzyro

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, including the results immunologic laboratory testing that show low C4 and functional C1- inhibitor levels</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by Allergist or Immunologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 months initially, 12 months for continuation</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Prophylactic treatment with Cinryze is limited to patients who experience one or more severe attacks per month, on average.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# HETLIOZ

## Products Affected
- Hetliz

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, other therapies tried and/or failed</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 months initial, 1 year continuation</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

Products Affected
- Juxtapid

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, prior therapy used, results of prior therapy</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 months for initiation, 6 months for continuation</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Patient must have a diagnosis of homozygous familial hypercholesterolemia. Liver function tests required at baseline and at least monthly during the first year of treatment.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# HUMIRA

## Products Affected
- Humira
- Humira Pediatric Crohns Start
- Humira Pen
- Humira Pen Crohns-UC-HS Start
- Humira Pen Psor-Uveits-Adol HS
- Humira(CF)
- Humira(CF) Pedi Crohns Starter
- Humira(CF) Pen Crohns-UC-HS
- Humira(CF) Pen Psor-Uv-Adol HS
- HUMIRA(CF) PEN SUBCUTANEOUS INJECTOR KIT 40 MG/0.4 ML

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>Concurrent use with another biologic DMARD or targeted synthetic DMARD.</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, concurrent medications, previous therapies tried</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>Crohn's disease (CD), 6 or older (initial therapy only). Ulcerative colitis (UC), adults.</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>RA/JIA/JRA/Ankylosing spondylitis, prescribed by or in consultation with rheumatologist. Psoriatic arthritis (PsA), prescribed by or in consultation with a rheumatologist or dermatologist. Plaque psoriasis (PP), prescribed by or in consultation with a dermatologist. UC/CD, prescribed by or in consultation with a gastroenterologist. HS - dermatologist.UV-ophthalmologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>initial 3 mo, cont tx 3 years.</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>RA initial, patient has tried one conventional synthetic DMARD for at least 3 months (note: patients who have already had a 3-month trial of a biologic for RA are not required to 'step back' and try a conventional synthetic DMARD). JIA/JRA initial. Tried another agent (e.g. MTX, sulfasalazine, leflunomide, NSAID, or biologic DMARD (eg, etanercept, abatacept, infliximab, anakinra, tocilizumab) or will be starting on adalimumab concurrently with MTX, sulfasalazine, or leflunomide. Approve without trying another agent if pt has absolute contraindication to MTX, sulfasalazine, or leflunomide or if pt has aggressive disease. PP initial-approve if the patient meets one of the following criteria: 1) pt has tried at least one traditional systemic agent (eg, MTX, cyclosporine, acitretin, PUVA) for at least 3 months, unless intolerant (note: pts who...</td>
</tr>
<tr>
<td>PA Criteria</td>
<td>Criteria Details</td>
</tr>
<tr>
<td>-------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>have already tried a biologic for psoriasis are not required to 'step back' and try a traditional agent first) OR 2) pt has a contraindication to MTX as determined by the prescribing physician. CD initial. Tried corticosteroids (CSs) or if CSs are contraindicated or if pt currently on CSs or patient has tried one other agent for CD (eg, azathioprine, 6-mercaptopurine, MTX, certolizumab, infliximab, ustekinumab, or vedolizumab) OR pt had ilecolonic resection OR enterocutaneous (perianal or abdominal) or rectovaginal fistulas. UC initial. Pt has tried a systemic therapy (eg, 6-mercaptopurine, azathioprine, CSA, tacrolimus, infliximab, golimumab SC, or a corticosteroid such as prednisone or methylprednisolone) for 2 months or was intolerant to one of these agents, or the pt has pouchitis and has tried therapy with an antibiotic, probiotic, corticosteroid enema, or mesalamine (Rowasa) enema. FDA approve indications cont tx - must respond to tx as determined by prescriber. HS - tried ONE other therapy (e.g., intralesional or oral corticosteroids, systemic antibiotics, isotretinoin). Clinical criteria incorporated into the Humira 40 mg quantity limit edit allow for approval of additional quantities to accommodate induction dosing. The allowable quantity is dependent upon the induction dosing regimen for the applicable FDA-labeled indications as outlined in product labeling.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Indications</th>
<th>All Medically-accepted Indications.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
**IBRANCE (S)**

**Products Affected**
- Ibrance

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>N/A</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by an oncologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## ICLUSIG

### Products Affected
- Iclusig

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical</td>
<td>Diagnosis, prior therapy used, result of prior therapy.</td>
</tr>
<tr>
<td>Information</td>
<td></td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by an oncologist or hematologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Liver function monitoring required at baseline and 3 months after initiation</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
**IDHIFA**

**Products Affected**
- Idhifa

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, previous treatments, and outcome.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescribed by or in consultation with a hematologist/oncologist.</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## IMBRUVICA

### Products Affected
- Imbruvica oral capsule 140 mg, 70 mg
- Imbruvica oral tablet

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>DIAGNOSIS, PRIOR TREATMENTS, RESPONSE TO THERAPY</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be prescribed by oncologist, hematologist, or transplant specialist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Formulary ID 20495, V#9
INBRIJA

Products Affected
- Inbrija inhalation capsule, w/inhalation device

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical</td>
<td>Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to LEVODOPA ORAL INHALATION.</td>
</tr>
<tr>
<td>Information</td>
<td></td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>Adult patients aged 18 years and older.</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by a neurologist.</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 months for initial authorization, 12 months for continuation.</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Required trial and failure of: 1) both carbidopa/levodopa IR and ER and, 2) at least one other Parkinson's Disease drug: entacapone, pramipexole, ropinirole, selegiline, rasagiline, or amantadine. Intention to continue use of carbidopa/levodopa.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## INCRELEX

### Products Affected
- Increlex

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>DIAGNOSIS, HEIGHT AND WEIGHT MEASUREMENTS, GH LEVEL, IGF-1 LEVEL</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>PRESCRIPTION MUST BE WRITTEN BY ENDOCRINOLOGIST</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 MONTHS INITIAL, 1 YEAR CONTINUATION</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
INHALED TOBRAMYCIN

Products Affected
- Tobi Podhaler inhalation capsule, w/inhalation device

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, therapies tried, and outcome</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescribed by Infectious disease specialist or pulmonologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 year</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
INLYTA

Products Affected
- Inlyta oral tablet 1 mg, 5 mg

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>DIAGNOSIS, PRIOR TREATMENTS, RESPONSE TO THERAPY</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>18 YEARS OF AGE AND OLDER</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>PRESCRIPTION MUST BE WRITTEN BY A ONCOLOGIST</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## INREBIC

### Products Affected
- Inrebic

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>Evaluate baseline thiamine levels prior to treatment initiation, do not initiate fedratinib in patients with thiamine deficiency. Replete thiamine prior to fedratinib initiation and during treatment if thiamine levels are low.</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, Other therapies tried with treatment response, baseline thiamine level, baseline platelet level</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescribed by Hematologist / Oncologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Documented baseline platelet count of at least 50,000 per cubic millimeter.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
### INTERFERON ALPHA

#### Products Affected
- Intron A injection
- Pegasys
- Pegasys ProClick subcutaneous pen injector 180 mcg/0.5 mL

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical</td>
<td>FOR HEPATITIS C: PATIENT WEIGHT, GENOTYPE, HCV-RNA QUANTITY AND DATE OF TEST,</td>
</tr>
<tr>
<td>Information</td>
<td>PRESENCE OF DIRRHOSIS (Y/N), TREATMENT HISTORY, HISTORY OF ANEMIA OR DEPRESSION.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 YEARS FOR INDICATIONS OTHER THAN HEPATITIS C. HEPC APPROVALS FROM 12-48 WKS BASED ON DRUG REGIMEN</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
INTUNIV

Products Affected
- guanfacine oral tablet extended release 24 hr

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical</td>
<td>DIAGNOSIS AND THERAPIES TRIED AND FAILED.</td>
</tr>
<tr>
<td>Information</td>
<td></td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 year</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
IRESSA

Products Affected
- Iressa

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, prior therapy used, response to prior therapy</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>PRESCRIPTION MUST BE WRITTEN BY ONCOLOGIST</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>GEFITINIB IS COVERED AS MONOTHERAPY</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# IVIG

## Products Affected
- Bivigam
- Cuvitru
- Flebogamma DIF intravenous solution
- Gammagard Liquid
- Gammagard S-D (IgA < 1 mcg/mL)
- Gammaked injection solution 1 gram/10 mL (10 %)
- Gammaplex
- Gammaplex (with sorbitol)
- Gamunex-C injection solution 1 gram/10 mL (10 %)
- Hizentra
- Hyqvia
- Octagam
- Privigen

## PA Criteria

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>DIAGNOSIS, OTHER THERAPIES TRIED AND FAILED, RESPONSE TO TREATMENT</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 MONTHS FOR INITIATION, 6 MONTHS FOR CONTINUATION</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>DIAGNOSIS AND ADMINISTRATION INFORMATION WILL BE REVIEWED TO DETERMINE IF COVERAGE IS AVAILABLE AS A MEDICARE PART B OR PART D BENEFIT</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
### JAKAFI

**Products Affected**
- Jakafi

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>DIAGNOSIS, OTHER TREATMENTS TRIED AND FAILED, CBC AT BASELINE AND PERIODICALLY AFTER INITIATION, HISTORY OF RBC TRANSFUSIONS</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>PRESCRIBER MUST BE A HEMATOLOGIST OR ONCOLOGIST</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
**JYNARQUE**

**Products Affected**
- Jynarque oral tablets, sequential

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>History of signs or symptoms of significant liver impairment or injury</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Documented diagnosis of polycystic kidney disease, ultrasound results</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescribed by endocrinology or nephrology</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>6 months initial, 1 year continuation</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## KALYDECO

### Products Affected
- Kalydeco

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis and the presence of one or more specific gene mutations that the drug is FDA approved to treat.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 months initially, 12 months for continuation</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# Prior Authorization Criteria
## Health Alliance Plan 2020
**Date Effective:** 02/01/2020

### Formulary ID 20495, V#9

## KINERET

### Products Affected
- Kineret

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, other therapies tried and/or failed</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by rheumatologist or pediatricist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 months initially, 6 months for continuation</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Coverage for gout is limited to patients who have tried a maximum tolerated dose of a xanthine oxidase inhibitor (i.e.: allopurinol)</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
Prior Authorization Criteria
Health Alliance Plan 2020
Date Effective: 02/01/2020

KISQALI

Products Affected
- Kisqali
- Kisqali Femara Co-Pack

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, other therapies previously tried, and the outcome.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescribed by or in consultation with an oncologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
KORLYM

Products Affected
- Korlym

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, other therapies tried and outcome, HbA1c</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescribed by endocrinologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 year</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Must have trial of ketoconazole or metyrapone therapy or have intolerance or contraindication to these medications. Must have failed surgery or not be a candidate for surgery. For continuation of therapy patient must show an improvement in HbA1c.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
KUVAN

Products Affected
- Kuvan oral powder in packet 100 mg
- Kuvan oral tablet, soluble

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical</td>
<td>DIAGNOSIS AND BASELINE AND FOLLOW UP PHENYLALANINE LEVELS. FOR CONTINUATION, MUST SHOW A 30% REDUCTION IN PHE LEVELS FROM BASELINE</td>
</tr>
<tr>
<td>Information</td>
<td></td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 MONTHS FOR INITIATION, 1 YEAR FOR CONTINUATION</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# Lenvima

**Products Affected**
- Lenvima

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>N/A</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by an oncologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Formulary ID 20495, V#9
# LEUKINE

## Products Affected
- Leukine injection recon soln

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>DIAGNOSIS</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>ACUTE MYELOID LEUKEMIA (AML): GREATER OR EQUAL TO 55 YEARS OLD.</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 MONTHS AT A TIME</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# LIBTAYO

## Products Affected
- Libtayo

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Covered Uses</td>
<td>All medically accepted indications not otherwise excluded from Part D.</td>
</tr>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, other therapies tried and/or failed, and response to prior therapy</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by or in consultation with an oncologist or hematologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 YEAR</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# LIDOCAINE TRANSDERMAL

## Products Affected
- lidocaine topical adhesive patch, medicated 5%
- lidocaine topical ointment

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>N/A</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 year</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## LINZESS

### Products Affected
- Linzess

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis and previous treatments</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 year</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Must have a failure, contraindication or intolerance to Amitza</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## Prior Authorization Criteria

### Health Alliance Plan 2020

**Date Effective:** 02/01/2020

**Formulary ID 20495, V#9**

---

## LOKELEMA

### Products Affected
- Lokelma

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis of hyperkalemia, confirmed with laboratory test within the past month.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>6 months for initiation, 1 year for continuation</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>For initiation, must have a failure, contraindication, or intolerance to sodium polystyrene sulfonate. For continuation, must show response to therapy as demonstrated by normal potassium levels and patient remains at high risk for recurrence of hyperkalemia.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>

---

Formulary ID 20495, V#9
# LONSURF

## Products Affected
- Lonsurf

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, other therapies tried and/or failed, and treatment response</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by an oncologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# LORBRENA

## Products Affected
- Lorbrena

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to treatment.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by an oncologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
LYNPARZA

**Products Affected**
- Lynparza oral tablet

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>DIAGNOSIS, PRIOR THERAPIES, GENETIC TESTING</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>PRESCRIPTION MUST BE WRITTEN BY ONCOLOGIST</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 months initiation, 6 months continuation</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Patients must have failed greater than equal to 3 prior courses of chemotherapy and have BRCA-positive or suspected BRCA-positive advanced ovarian cancer</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
MAVENCLAD

### Products Affected
- Mavenclad (10 tablet pack)
- Mavenclad (4 tablet pack)
- Mavenclad (5 tablet pack)
- Mavenclad (6 tablet pack)
- Mavenclad (7 tablet pack)
- Mavenclad (8 tablet pack)
- Mavenclad (9 tablet pack)

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>Excluded for patients with HIV, active chronic hepatitis, or tuberculosis.</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>For MS Diagnosis, EDSS score, relapse history, physical or cognitive disability, TB test</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by a neurologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 year</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>For MS-failure of at least two of the following: glatiramer or glatopa AND either Gilenya, Betaseron, or Avonex.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# MAYZENT

## Products Affected
- Mayzent

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, EDSS score, relapse history, and physical or cognitive disability</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by a neurologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 year</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Failure of at least two of the following: glatiramer or glatopa AND either Gilenya, Betaseron, or Avonex.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# MEDICALLY ACCEPTED USE

## Products Affected
- Auryxia
- megestrol oral suspension 400 mg/10 mL (40 mg/mL), 625 mg/5 mL
- megestrol oral tablet
- topiramate oral capsule, sprinkle
- topiramate oral tablet
- zonisamide

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>N/A</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# MEKINIST

## Products Affected
- Mekinist oral tablet 0.5 mg, 2 mg

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>Wild-type BRAF melanoma</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, prior therapy used, result of prior therapy. Documentation of BRAF mutation, as detected using an FDA-approved test.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by an oncologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# MEKTOVI

## Products Affected
- Mektovi

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to treatment.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by an oncologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Must be used in combination with encorafenib.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
### METHADONE

**Products Affected**
- methadone oral solution
- methadone oral tablet

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical</td>
<td>Diagnosis and any prior treatments.</td>
</tr>
<tr>
<td>Information</td>
<td></td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>6 months</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Monitor for possible misuse, including early refill</td>
</tr>
<tr>
<td></td>
<td>history and multiple treating physicians</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
METHAMPHETAMINE

**Products Affected**
- methamphetamine

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, other therapies previously tried and failed, and response to treatment</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 year</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>For the treatment of attention deficit disorder patient must have a trial of both methylphenidate and amphetamine/dextroamphetamine or rationale as to why these treatments are not suitable.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
### MIRVASO

#### Products Affected
- Mirvaso topical gel with pump

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Documentation of diagnosis and other treatments tried and outcome.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 year</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>For the treatment of acne rosacea: doxycycline (oral) and topical metronidazole.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# MOVANTIK

## Products Affected
- Movantik

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>Will not be approved for cancer related pain</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Documented diagnosis of opiate induced constipation (non-cancer pain)</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 year</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Patient must have a trial of or contraindication to at least two different classes of laxative agents including bulk, osmotic, or stimulant laxatives.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
**MULPLETA**

**Products Affected**
- Mulpleta

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis and platelet count</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Must be prescribed by a hematologist, oncologist, or gastroenterologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 month</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Patient must be scheduled to undergo a pre-planned medical or dental procedure with treatment beginning 8 to 14 days prior to the scheduled procedure. Patients should undergo their procedure 2 to 8 days after the last dose.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
MULTIPLE SCLEROSIS

Products Affected
- Aubagio
- Avonex intramuscular pen injector kit
- Avonex intramuscular syringe kit
- Avonex vial kit
- Betaseron subcutaneous kit
- Gilenia oral capsule 0.5 mg
- glatiramer
- Glatopa
- Plegridy
- Tecfidera

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical</td>
<td>Diagnosis, EDSS score, relapse history, and physical or cognitive disability</td>
</tr>
<tr>
<td>Information</td>
<td></td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber</td>
<td>Prescription must be written by a neurologist</td>
</tr>
<tr>
<td>Restrictions</td>
<td></td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Patient must have a trial of or contraindication to glatiramer or glatopa prior to initiating the other drugs listed in this criteria.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
**MYALEPT**

**Products Affected**
- Myalept

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, prior therapy used, result of prior therapy</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 months for initiation, 1 year for continuation</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# NATPARA

## Products Affected
- Natpara

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>DIAGNOSIS, BASELINE SERUM CALCIUM AND 25-HYDROXYVITAMIN D LEVELS</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>MUST BE PRESCRIBED BY AN ENDOCRINOLOGIST</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 year</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# NAYZILAM

## Products Affected
- Nayzilam

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to midazolam.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by a neurologist.</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 year</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
NERLYNX

Products Affected
- Nerlynx

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, previous treatments, and outcome.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescribed by or in consultation with an oncologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Approve for continuation of prior therapy if treatment duration of Nerlynx has not exceeded a total of 12 months</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
**NEUPRO**

**Products Affected**
- Neupro

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, other therapies tried and/or failed, frequency of symptoms</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 year</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Patient must have a trial of or contraindication to two of the following therapies prior to coverage of Neupro: pramipexole, ropinirole, or carbidopa/levodopa.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
NEXAVAR

Products Affected
- Nexavar

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical</td>
<td>DIAGNOSIS, PRIOR THERAPIES, AND TREATMENT RESPONSE</td>
</tr>
<tr>
<td>Information</td>
<td></td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>PRESCRIPTION MUST BE WRITTEN BY ONCOLOGIST</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# NINLARO

## Products Affected
- Ninlaro

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, other therapies tried and/or failed, and treatment response. Used in combination with Revlimid (lenalidomide) and dexamethasone.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by an oncologist or hematologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Must have an intolerance or contraindication to Velcade</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
**NOXAFIL**

### Products Affected
- Noxafil oral suspension

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, therapies tried, and outcome</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescribed Infectious disease specialist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>6 months</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>For the treatment of aspergillosis patient must have failure of, intolerance or contraindication to vorconizole OR rationale as to why vorconizole is not suitable.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
**NUBEQA**

**Products Affected**
- Nubeqa

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to darolutamide.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by an oncologist or urologist.</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 year</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
NUCALA

Products Affected
- Nucala

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>For patients with asthma: allergen test, baseline FEV1, FEV1 following bronchodilator, asthma medical history (including medications, emergency department visits, and hospitalizations), baseline eosinophil count. For patients with eosinophilic granulomatosis with polyangiitis: documentation of diagnosis, prior therapies, and the outcome.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Pulmonologist, immunologist, allergist or rheumatologist.</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 months for initial, 1 year for continuation</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>For patients with asthma: must be currently receiving inhaled and/or oral corticosteroid treatment, AND have a baseline eosinophil count of 300 cells/mcL or greater within previous 12 months or 150 cell/mcL within previous 6 weeks.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# NUEDEXTA

## Products Affected
- Nuedexta

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>N/A</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 year</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
**NUPLAZID**

**Products Affected**
- Nuplazid oral capsule
- Nuplazid oral tablet 10 mg

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Parkinson's disease psychosis: Diagnosis of Parkinson's disease. Patient has at least one of the following: hallucinations or delusions.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by or in consultation with a neurologist or psychiatrist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
OCALIVA

Products Affected
- Ocaliva

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, other therapies tried and failed, and response to therapy, baseline alkaline phosphatase (ALP) level for initiation, and ALP levels after first 3 months of therapy and then yearly for continuation of therapy.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 months for initial and 1 year for continuation</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Use in combination with ursodiol in patients with an inadequate biochemical response to treatment (elevated ALP levels) with ursodiol dosed at 13-15 mg/kg/day for at least 1 year, may be used as monotherapy in patients unable to tolerate ursodiol. Must show improvement in ALP levels for continuation.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## OCTREOTIDE

### Products Affected
- octreotide acetate injection solution

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, other therapies tried and failed</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 year</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# ODOMZO

## Products Affected
- Odomzo

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Patient has recurring disease following surgery or radiation OR patient is not a candidate for surgery or radiation therapy</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by an oncologist or dermatologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# ORENCIA

## Products Affected
- Ocrecia
- Ocrecia ClickJect

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>DIAGNOSIS AND OTHER THERAPIES TRIED AND FAILED, NEGATIVE TB TEST</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>PRESCRIPTION MUST BE WRITTEN BY A RHEUMATOLOGIST</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 MONTHS INITIAL, 2 YEARS CONTINUATION</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>PATIENT MUST HAVE A DOCUMENTED FAILURE OR CONTRAINDICATION TO AT LEAST ONE NON-BIOLOGIC DMARD (including but not limited to methotrexate, hydroxychloroquine, sulfasalazine, azathioprine).</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## ORFADIN

### Products Affected
- Orfadin

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>DIAGNOSIS AND WEIGHT</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>PRESCRIPTION MUST BE WRITTEN BY AN ENDOCRINOLOGIST, GASTROENTEROLOGIST, HEMATOLOGIST, METABOLIC SPECIALIST, OR NEPHROLOGIST</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 MONTHS INITIAL, 1 YEAR CONTINUATION</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>CLOSE MONITORING OF DISEASE MARKERS (ERYTHROCYTE PBG-SYNTHASE ACTIVITY, URINE 5-ALA, SUCCINYLACETONE) DURING THE FIRST 3 MONTHS OF TREATMENT TO ENSURE NORMALIZATION</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
**ORKAMBI**

**Products Affected**
- Orkambi oral granules in packet
- Orkambi oral tablet

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Patient has a diagnosis of cystic fibrosis (CF) AND Patient is homozygous for the F508del mutation in the CF transmembrane conductance regulator (CFTR) gene AND The presence of the mutation was documented by an FDA-cleared cystic fibrosis mutation test.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>For renewal. Patient is benefiting from treatment (i.e., improvement in lung function [forced expiratory volume in one second [FEV1], decreased number of pulmonary exacerbations)</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
ORLISSA

Products Affected
- Orilissa

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, prior therapies, and result of prior therapy.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 year</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Must have a failure, contraindication, or intolerance to a continuous hormonal contraceptive AND progestin therapy (e.g. medroxyprogesterone, norethindrone).</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## OTEZLA

### Products Affected
- Otezla
- Otezla Starter oral tablets, dose pack 10 mg (4)-20 mg (4)-30 mg (47)

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, prior therapy used, result of prior therapy</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Must be prescribed by a Rheumatologist or Dermatologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 months for initiation, 2 years for continuation</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>For arthritis conditions, must have a trial of or contraindication to one non-biologic DMARD (including but not limited to methotrexate, hydroxychloroquine, sulfasalazine, azathioprine). For diagnosis of plaque psoriasis, must have a trial of or contraindication to cyclosporine or methotrexate</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
### OXERVATE

#### Products Affected
- Oxervate

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Covered Uses</td>
<td>All medically accepted indications not otherwise excluded from Part D.</td>
</tr>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, prior therapies, and result of prior therapy.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by an ophthalmologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>8 weeks</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## Prior Authorization Criteria

**Health Alliance Plan 2020**

Date Effective: 02/01/2020

### OXYCONTIN

**Products Affected**
- oxycodone oral tablet, oral only, ext.rel.12 hr

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>DIAGNOSIS, OTHER THERAPIES TRIED AND FAILED, RESPONSE TO TREATMENT, OTHER OPIATES CURRENTLY BEING USED</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>6 MONTHS</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>MONITOR FOR POTENTIAL MISUSE INCLUDING EARLY REFILL HISTORY, MULTIPLE CONCURRENT LONG ACTING OPIATES OVER 3 MONTH PERIOD, AND MULTIPLE TREATING PHYSICIANS</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
### PALYNZIQ

**Products Affected**
- Palynziq

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, prior treatments, and outcome. Baseline and follow up phenylalanine (Phe) concentrations.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 months for initial, 1 year for continuation</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Must have phenylalanine (Phe) concentrations greater than 600 micromol/L on existing management, and a failure, contraindication, or intolerance to Kuvan.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# PANRETIN

## Products Affected
- Panretin

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>NOT INDICATED WHEN SYSTEMIC ANTI-KS THERAPY IS REQUIRED.</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>N/A</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>6 MONTHS</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
PHOSPHODIESTERASE-5 INHIBITORS FOR PAH

Products Affected
- Alyq
- sildenafil (Pulmonary Arterial Hypertension) oral
- tadalafil (pulmonary arterial hypertension) oral tablet 20 mg

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, right heart cath results</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>For PAH, if prescribed by, or in consultation with, a cardiologist or a pulmonologist.</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Pulmonary arterial hypertension (PAH) WHO Group 1, are required to have had a right-heart catheterization to confirm diagnosis of PAH to ensure appropriate medical assessment.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
PIQRAY

Products Affected
- Piqray

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical</td>
<td>Diagnosis, prior therapies</td>
</tr>
<tr>
<td>Information</td>
<td></td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Breast Cancer. Approve if the patient meets</td>
</tr>
<tr>
<td></td>
<td>the following criteria (A, B, C, D, and E):</td>
</tr>
<tr>
<td></td>
<td>A) The patient is a postmenopausal female or</td>
</tr>
<tr>
<td></td>
<td>a male AND B) The patient has advanced or</td>
</tr>
<tr>
<td></td>
<td>metastatic hormone receptor (HR)-positive</td>
</tr>
<tr>
<td></td>
<td>disease AND C) The patient has human</td>
</tr>
<tr>
<td></td>
<td>epidermal growth factor receptor 2 (HER2)-</td>
</tr>
<tr>
<td></td>
<td>negative disease AND D) The patient has PIK3CA-</td>
</tr>
<tr>
<td></td>
<td>mutated breast cancer as detected by an</td>
</tr>
<tr>
<td></td>
<td>approved test AND E) The patient has</td>
</tr>
<tr>
<td></td>
<td>progressed on or after at least one prior</td>
</tr>
<tr>
<td></td>
<td>endocrine-based regimen (e.g., anastrozole,</td>
</tr>
<tr>
<td></td>
<td>letrozole, exemestane, Faslodex, tamoxifen,</td>
</tr>
<tr>
<td></td>
<td>toremifene).</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## Prior Authorization Criteria

**Health Alliance Plan 2020**

**Date Effective:** 02/01/2020

### POMALYST

#### Products Affected
- Pomalyst

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, prior therapy used, result of prior therapy.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by an oncologist or hematologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## PROLIA

### Products Affected
- Prolia

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>Concomitant use with other medications for osteoporosis (eg, denosumab [Prolia], bisphosphonates, raloxifene, calcitonin nasal spray [Fortical], abaloparatide), except calcium and Vitamin D.</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>N/A</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Treatment of postmenopausal osteoporosis/Treatment of osteoporosis in men (to increase bone mass) [a man is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression], approve if the patient meets one of the following: 1. has had inadequate response after 12 months of therapy with an oral bisphosphonate, had osteoporotic fracture or fragility fracture while receiving an oral bisphosphonate, or intolerability to an oral bisphosphonate, OR 2. the patient cannot take an oral bisphosphonate because they cannot swallow or have difficulty swallowing, they cannot remain in an upright position, or they have a pre-existing GI medical condition, OR 3. pt has tried an IV bisphosphonate (ibandronate or zoledronic acid), OR 4. the patient has severe renal impairment (eg, creatinine clearance less than 35 mL/min) or chronic kidney disease, or if the patient has an osteoporotic fracture or fragility fracture. Treatment of bone loss in patient at high risk for fracture receiving ADT for nonmetastatic prostate cancer, approve if the patient has prostate cancer that is not metastatic to the bone and the patient is receiving ADT (eg, leuprolide, triptorelin, goserelin) or the patient has undergone a bilateral orchiectomy. Treatment of bone loss (to increase bone mass) in patients at high risk for fracture receiving adjuvant AI therapy for breast cancer,</td>
</tr>
</tbody>
</table>
## Prior Authorization Criteria

**Health Alliance Plan 2020**

**Date Effective:** 02/01/2020

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>approve if the patient has breast cancer that is not metastatic to the bone and in receiving concurrent AI therapy (eg, anastrozole, letrozole, exemestane). Treatment of GIO, approve if pt tried one oral bisphosphonate OR pt cannot take an oral bisphosphonate because the patient cannot swallow or has difficulty swallowing or the patient cannot remain in an upright position post oral bisphosphonate administration or has a pre-existing GI medical condition (eg, patient with esophageal lesions, esophageal ulcers, or abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]), OR pt has tried zoledronic acid (Reclast), OR pt has severe renal impairment (CrCL less than 35 mL/min) or has CKD or has had an osteoporotic fracture or fragility fracture.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Indications</th>
<th>All Medically-accepted Indications.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
PROMACTA

Products Affected
- Promacta

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical</td>
<td>Diagnosis, other therapies tried and/or failed, and platelet count</td>
</tr>
<tr>
<td>Information</td>
<td></td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>INITIAL FILL FOR 6 MONTHS, 1 YEAR THEREAFTER</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
**PROVIGIL**

**Products Affected**
- modafinil

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>N/A</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>Patients must be greater than or equal to 17 years of age.</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 year</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Excessive sleepiness due to SWSD if the patient is working at least 5 overnight shifts per month. Adjunctive/augmentation treatment for depression in adults if the patient is concurrently receiving other medication therapy for depression.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
PULMONARY FIBROSIS

Products Affected
- Esbriet
- Ofev

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>liver function</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>prescriber must be a pulmonologist.</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 year</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# PULMONARY HYPERTENSION

## Products Affected
- ambrisentan
- bosentan
- Letairis
- Opsumit
- sildenafil (Pulmonary Arterial Hypertension) oral
- Tracleer
- Ventavis
- Tyvaso

## Criteria Details

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>CONFIRMATION OF DIAGNOSIS OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP 1), PRIOR THERAPIES USED, DOCUMENTATION OF RESPONSE TO THERAPY</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>PRESCRIPTION MUST BE WRITTEN BY PULMONOLOGIST OR CARDIOLOGIST</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Ventavis will also be reviewed for coverage under part B versus part D. Sildenafil must be tried prior to the use of the drugs included in this criteria, unless there is a contraindication to sildenafil.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## PURIXAN

### Products Affected
- Purixan

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>DIAGNOSIS, PRIOR TREATMENTS, RESPONSE TO THERAPY</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>prescriber must be a oncologist or hematologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# RELISTOR

## Products Affected
- Relistor oral
- Relistor subcutaneous solution
- Relistor subcutaneous syringe

## PA Criteria

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Info</td>
<td>Diagnosis and prior therapies tried and failed</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 months for initiation, 1 year for continuation</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>For the treatment of opioid-induced constipation associated with chronic noncancerous pain: prior trial of or contraindication to at least one class of laxative agents (including bulk, osmotic, or stimulant laxatives) AND Amitiza. For all other conditions: a trial of or contraindication to at least two different classes of laxative agents (including bulk, osmotic, or stimulant laxatives)</td>
</tr>
</tbody>
</table>

## Indications
- All Medically-accepted Indications.

## Off-Label Uses
- N/A
REPATHA

**Products Affected**
- Repatha
- Repatha Pushtronex
- Repatha SureClick

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>Concurrent use of Juxtapid or Praluent.</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>LDL-C and response to other agents, prior therapies tried, medication adverse event history, medical history</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>ASCVD/HeFH/Primary Hyperlipidemia - 18 yo and older, HoFH 13 yo and older.</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescribed by, or in consultation with, a cardiologist, endocrinologist, or a physician who focuses in the treatment of CV risk management and/or lipid disorders</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>Approve for 3 years for ASCVD/HeFH/HoFH. Approve for 1 year for primary hyperlipidemia.</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Under CMS Review</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## REVCOCI

### Products Affected
- Revcovi injection

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Covered Uses</strong></td>
<td>All medically accepted indications not otherwise excluded from Part D.</td>
</tr>
<tr>
<td><strong>Exclusion Criteria</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Required Medical Information</strong></td>
<td>Documented diagnosis of Adenosine deaminase (ADA) deficiency, IgA, IgM, and IgG levels, CBC, and presence of mutations in the ADA gene at 20q13.11</td>
</tr>
<tr>
<td><strong>Age Restrictions</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Prescriber Restrictions</strong></td>
<td>Prescription must be written by immunologist</td>
</tr>
<tr>
<td><strong>Coverage Duration</strong></td>
<td>1 year</td>
</tr>
<tr>
<td><strong>Other Criteria</strong></td>
<td>N/A</td>
</tr>
</tbody>
</table>
## REVLIMID

### Products Affected
- Revlimid

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis and previous therapies or drug regimens tried.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>MCL-approve if the patient meets one of the following 1) Pt has tried two prior therapies or therapeutic regimens OR 2) Pt has tried one prior therapy or therapeutic regimen and cannot take Velcade according to the prescribing physician. MDS-approve if the patient meets one of the following: 1) Pt has symptomatic anemia, OR 2) Pt has transfusion-dependent anemia, OR 3) Pt has anemia that is not controlled with an erythroid stimulating agent (eg, Epogen, Procrit [epoetin alfa injection], Aranesp [darbepoetin alfa injection]). Diffuse, Large B Cell Lymphoma (Non-Hodgkin's Lymphoma)-approve if the pt has tried one other medication treatment regimen. Myelofibrosis-approve if the pt has tried one other therapy.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
Prior Authorization Criteria
Health Alliance Plan 2020
Date Effective: 02/01/2020

**RINVOQ**

**Products Affected**
- Rinoq ER

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, prior therapy used, result of prior therapy. If continuation, prior</td>
</tr>
<tr>
<td></td>
<td>response to UPADACITINIB.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by a rheumatologist.</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 months for initial authorization, 12 months for continuation.</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Documented trial and failure of triple therapy with oral non-biologic DMARDs, a</td>
</tr>
<tr>
<td></td>
<td>combination of methotrexate, hydroxychloroquine and sulfasalazine, for at least</td>
</tr>
<tr>
<td></td>
<td>three months or a contraindication to triple therapy.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
### ROZLYTREK

**Products Affected**
- Rozlytrek oral capsule 100 mg, 200 mg

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to ENTRECTINIB.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by an oncologist.</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 year</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Formulary ID 20495, V#9
## Prior Authorization Criteria

Health Alliance Plan 2020

Date Effective: 02/01/2020

---

### RUBRACA

#### Products Affected
- Rubraca

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Exclusion Criteria</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Required Medical Information</strong></td>
<td>Ovarian cancer: Diagnosis of advanced ovarian cancer. Presence of deleterious BRCA mutation as detected by an FDA-approved diagnostic test (e.g., Foundation Focus CDxBRCA Assay). History of failure, contraindication, or intolerance to two or more chemotherapies (e.g., cisplatin, carboplatin).</td>
</tr>
<tr>
<td><strong>Age Restrictions</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Prescriber Restrictions</strong></td>
<td>Prescribed by or in consultation with an oncologist</td>
</tr>
<tr>
<td><strong>Coverage Duration</strong></td>
<td>2 years</td>
</tr>
<tr>
<td><strong>Other Criteria</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td><strong>Off-Label Uses</strong></td>
<td>N/A</td>
</tr>
</tbody>
</table>
## RYDAPT

### Products Affected
- Rydapt

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Acute Myeloid Leukemia (AML): Newly diagnosed acute myeloid leukemia (AML), FMS-like tyrosine kinase 3 (FLT3) mutation-positive as detected by a U.S. Food and Drug Administration (FDA)-approved test, used in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. Aggressive Systemic Mastocytosis (ASM), Systemic Mastocytosis with Associated Hematological Neoplasm (SM-AHN), Mast Cell Leukemia (MCL): Diagnosis of one of the following: aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>All indications: Prescribed by or in consultation with a hematologist or oncologist.</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Approve for continuation of prior therapy</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
### SAMSCA

**Products Affected**
- Samsca

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, patient has a serum sodium less than 125 mEq/L at baseline, OR member has less marked hyponatremia (serum sodium less than 135 mEq/L at baseline) AND is symptomatic (e.g. nausea, vomiting, headache, lethargy, confusion, and baseline LFTs)</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescribed by endocrinology or nephrology</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 month</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Patient must have documented failure of two other therapies (e.g. fluid restriction, furosemide, demeclocycline).</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## SAVELLA

### Products Affected
- Savella oral tablet
- Savella oral tablets, dose pack

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>DIAGNOSIS OF FIBROMYALGIA, RESPONSE TO THERAPY</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 YEAR</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>MUST HAVE TREATMENT FAILURE, INTOLERANCE, OR CONTRAINDICATION TO MAXIMALLY TOLERATED GABAPENTIN AND DULOXETINE.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
**SIGNIFOR**

**Products Affected**
- Signifor

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis and other treatments tried and failed. Documentation: of surgery with response (if performed), or when surgery is not a treatment option.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by an endocrinologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 months for initiation, 6 months for continuation.</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# SIRTURO

## Products Affected
- Sirturo

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, other therapies tried and/or failed. ECG and liver function tests are required at baseline and at intervals as specified in the FDA prescribing information to monitor for potentially severe adverse events.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by a infectious disease specialist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>24 weeks</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Drug therapy must be directly observed. Use of Sirturo is reserved for MDR-TB where other treatment options cannot be used for safety or efficacy reasons.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
SKYRIZI

Products Affected
- Skyrizi subcutaneous syringe kit

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, prior therapy used, result of prior therapy</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Must be prescribed by a Dermatologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>For diagnosis of plaque psoriasis, must have a trial of or contraindication to cyclosporine or methotrexate</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## SORIATANE

### Products Affected
- acitretin

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>Female patients who are pregnant or planning to become pregnant within the next three years</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, other therapies tried and/or failed</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by dermatologist, oncologist, or transplant physician</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 months for initiation, 6 months for continuation</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>For the treatment of psoriasis, patient must have a trial of or contraindication to topical therapy and methotrexate. For the prevention of skin cancer in solid organ transplant patients, Soriatane will be covered for patients who develop multiple (greater than 5) squamous cell carcinoma (SCC) lesions per year, aggressive SCC, or accelerated development of SCC</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Formulary ID 20495, V#9
**SPRITAM**

**Products Affected**
- Spritam

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, therapies tried, and outcome</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescribed by Neurologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Rationale as to why generic levetiracetam is not suitable.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
**SPRYCEL**

**Products Affected**
- Sprycel

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>N/A</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>PRESCRIPTION MUST BE WRITTEN BY ONCOLOGIST</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Must have a failure, intolerance or contraindication to imatinib.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
**STELARA**

**Products Affected**
- Stelara subcutaneous

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical</td>
<td>Diagnosis, prior therapies, and result of prior therapy. TB test results</td>
</tr>
<tr>
<td>Information</td>
<td></td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescribed by gastroenterologist, dermatologist or rheumatologist.</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 year</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>For arthritis conditions, must have a trial of or contraindication to one non-</td>
</tr>
<tr>
<td></td>
<td>biologic DMARD (including but not limited to methotrexate, hydroxychloroquine,</td>
</tr>
<tr>
<td></td>
<td>sulfasalazine, azathioprine). For diagnosis of plaque psoriasis, must have a</td>
</tr>
<tr>
<td></td>
<td>trial of or contraindication to cyclosporine or methotrexate. For Crohn's disease,</td>
</tr>
<tr>
<td></td>
<td>must have trial of or contraindication to at least one non-biologic conventional</td>
</tr>
<tr>
<td></td>
<td>therapy, including but not limited to sulfasalazine, mesalamine, azathioprine, or</td>
</tr>
<tr>
<td></td>
<td>methotrexate.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
### Products Affected
- Stivarga

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, prior therapy used, result of prior therapy. If continuation, prior</td>
</tr>
<tr>
<td></td>
<td>response to regorafenib. LFT lab test results are needed for continuation</td>
</tr>
<tr>
<td></td>
<td>treatment.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by an oncologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## SUTENT

### Products Affected
- Sutent

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>DIAGNOSIS, PRIOR THERAPIES, AND TREATMENT RESPONSE. DOCUMENTATION OF FAILURE OF IMATINIB FOR PATIENTS WITH GIST. DOCUMENTATION OF FAILURE OF VOTRIENT FOR PATIENTS WITH RENAL CELL CARCINOMA. IF NO PREVIOUS FAILURE, RATIONALE AS TO WHY PREFERRED AGENT CANNOT BE USED</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>PRESCRIPTION MUST BE WRITTEN BY ONCOLOGIST</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>GIST PATIENTS REQUIRE A FOLLOW-UP CT SCAN BETWEEN 8 AND 12 WEEKS.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Formulary ID 20495, V#9
# SYLATRON

## Products Affected
- Sylatron
- Pegintron

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>HISTORY OF HEPATITIS OR HEPATIC DECOMPENSATION</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>DIAGNOSIS OF MALIGNANT MELANOMA WITH EVIDENCE OF NODAL INVOLVEMENT</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>18 YEARS AND OLDER</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>PRESCRIBER MUST BE ONCOLOGIST OR DERMATOLOGIST</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>6 MONTHS</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>MONITOR FOR NEUROPSYCHIATRIC DISORDERS, TOXICITY, AND NEW OR WORSENING RETINOPATHY</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## SYMDEKO

### Products Affected
- Symdeko

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis of CF AND homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence. If the patients genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use. FEV1 at baseline and continuation, baseline LFT and continuation, review for drug interactions CYP3A inducers</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Must be prescribed by a pulmonologist or doctor specializing in cystic fibrosis</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>6 months initial, 1 year continuation</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>For renewal, Patient is benefiting from treatment (i.e., improvement in lung function [forced expiratory volume in one second (FEV1)], decreased number of pulmonary exacerbations)</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
**SYMLIN**

**Products Affected**
- SymlinPen 120
- SymlinPen 60

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>GASTROPARESIS OR USE OF DRUGS TO STIMULATE GASTROINTESTINAL MOTILITY</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>HBA1C AND CURRENT DIABETES MEDICATIONS</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 YEAR</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## SYMPAZAN

### Products Affected
- Sympazan oral film 10 mg, 20 mg, 5 mg

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, prior therapy used, result of prior therapy.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Must have failure, intolerance, or contraindication to generic clobazam</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## SYNRIBO

### Products Affected
- Synribo

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, prior therapy used, result of prior therapy.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by an oncologist or hematologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
TAFAMIDIS

Products Affected
- Vyndamax
- Vyndaqel

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Confirmation of diagnosis with appropriate testing.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by a cardiologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 year</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# TAFINLAR

## Products Affected
- Tafinlar

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>Wild-type BRAF melanoma</td>
</tr>
<tr>
<td>Required Medical</td>
<td>Diagnosis, prior therapy used, result of prior therapy. Documentation of</td>
</tr>
<tr>
<td>Information</td>
<td>BRAF mutation, as detected using an FDA-approved test.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by an oncologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## TAGRISSO

### Products Affected
- Tagrisso

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis supported with an approved test for the detection of mutations named in FDA label found in tumor or plasma specimens. Other therapies tried and responses to treatments.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescribed by an oncologist.</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
TALZENNA

Products Affected
- Talzenna

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical</td>
<td>Diagnosis, prior therapy used, result of prior therapy. If continuation, prior</td>
</tr>
<tr>
<td>Information</td>
<td>response to treatment.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by an oncologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## TARCEVA

### Products Affected
- erlotinib
- Tarceva

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>DIAGNOSIS, PRIOR THERAPIES, AND TREATMENT RESPONSE</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>PRESCRIPTION MUST BE WRITTEN BY ONCOLOGIST</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## TASIGNA

### Products Affected
- Tasigna oral capsule 150 mg, 200 mg, 50 mg

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>DIAGNOSIS, OTHER THERAPIES TRIED AND FAILED, RESPONSE TO TREATMENT, POTENTIAL DRUG INTERACTIONS</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>PRESCRIPTION MUST BE WRITTEN BY AN ONCOLOGIST</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Must have a failure, intolerance or contraindication to imatinib and Sprycel.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Formulary ID 20495, V#9
## TAVALISSE

### Products Affected
- Tavalisse

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, other therapies tried, outcome, and platelet count less than 50,000/microL for at least 3 months</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Must be prescribed by a hematologist or oncologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 months</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Patient must have a failure, contraindication, or intolerance to at least two of the following therapies: corticosteroids, IVIG, Rituxan, or Promacta. For continuation of therapy the platelet counts must be to a level sufficient to avoid clinically important bleeding.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# TAZORAC

## Products Affected
- tazarotene
- Tazorac topical cream 0.05 %
- Tazorac topical gel

## Exclusion Criteria
- N/A

## Required Medical Information
- DIAGNOSIS, OTHER THERAPIES TRIED AND FAILED.

## Age Restrictions
- N/A

## Prescriber Restrictions
- N/A

## Coverage Duration
- 1 YEAR

## Other Criteria
- N/A

## Indications
- All Medically-accepted Indications.

## Off-Label Uses
- N/A
### TEGSEDI

**Products Affected**
- Tegsedi

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis of polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR). For continuation of therapy, demonstrated positive response to therapy (improved neurologic impairment, motor function, or slowing of disease progression)</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Must be prescribed by a geneticist or neurologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>6 months for initiation, 1 year for continuation</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## TEKTURNA

### Products Affected

- Tekturna
- Tekturna HCT

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>DIAGNOSIS AND OTHER THERAPIES TRIED AND FAILED.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 YEAR</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>MUST SEE CONTRAINDICATION TO OR FAILURE OF 2 MEDICATIONS THAT BELONG TO DIFFERENT CLASSES OF ANTIHYPERTENSIVE MEDICATIONS. DIFFERENT CLASSES ALPHA BLOCKERS, BETA BLOCKERS, CALCIUM CHANNEL BLOCKERS, DIURETICS, ACE-INHIBITORS, ANGIOTENSIN-RECEPTOR BLOCKERS, OR VASODILATORS.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# TESTOSTERONE

## Products Affected
- Testosterone transdermal gel in metered-dose pump 12.5 mg/1.25 gram (1%), 20.25 mg/1.25 gram (1.62%)
- Testosterone transdermal gel in packet

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis of primary hypogonadism (congenital or acquired) in males. Diagnosis of secondary (hypogonadotropic) hypogonadism (congenital or acquired) in males. Hypogonadism (primary or secondary) in males, serum testosterone level. [Man is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression.]</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 year</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Hypogonadism (primary or secondary) in males - initial therapy, approve if all of the following criteria are met: 1) patient has persistent signs and symptoms of androgen deficiency (pre-treatment) [e.g., depressed mood, decreased energy, progressive decrease in muscle mass, osteoporosis, loss of libido, AND 2) patient has had two pre-treatment serum testosterone (total or available) measurements, each taken in the morning on two separate days, AND 3) the two serum testosterone levels are both low, as defined by the normal laboratory reference values. hypogonadism has been confirmed by a low for age serum testosterone (total or free) level defined by the normal laboratory reference values. Hypogonadism (primary or secondary) in males - continuing therapy, approve if the patient meets all of the following criteria: 1) patient has persistent signs and symptoms of androgen deficiency (pre-treatment) AND 2) patient had at least one pre-treatment serum testosterone level that was low. [Note: male is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression.]</td>
</tr>
<tr>
<td>PA Criteria</td>
<td>Criteria Details</td>
</tr>
<tr>
<td>----------------</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
**TIBSOVO**

**Products Affected**
- Tibsovo

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to treatment.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by an oncologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
**TRANSMUCOSAL IMMEDIATE RELEASE FENTANYL**

**Products Affected**
- fentanyl citrate buccal lozenge on a handle
- Lazanda

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Exclusion Criteria</strong></td>
<td>NOT APPROVED FOR PATIENTS WHO ARE NOT TOLERANT TO OPIOID THERAPY AND ARE NOT RECEIVING LONG ACTING OPIATE THERAPY</td>
</tr>
<tr>
<td><strong>Required Medical Information</strong></td>
<td>Diagnosis and trial of two formulary short-acting opioid analgesics such as oxycodone, morphine, or hydromorphone as immediate-release (IR) tablet formulations or oral solution.</td>
</tr>
<tr>
<td><strong>Age Restrictions</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Prescriber Restrictions</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Coverage Duration</strong></td>
<td>6 MONTHS AT A TIME</td>
</tr>
<tr>
<td><strong>Other Criteria</strong></td>
<td>DOCUMENTATION AS TO WHY A UNIQUE METHOD OF ADMINISTRATION IS NEEDED AND A TRADITIONAL SHORT ACTING ORAL OPIATE MEDICATION IS NOT SUITABLE. PRIOR TO COVERAGE, THE PLAN WILL DETERMINE WHETHER THE DIAGNOSIS MEETS PART D REQUIREMENTS FOR APPROVAL.</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td><strong>Off-Label Uses</strong></td>
<td>N/A</td>
</tr>
</tbody>
</table>
TRELEGY

Products Affected

- Trelegy Ellipta

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, other therapies tried, outcome, baseline FEV1, and history of ER visits/hospitalizations.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Member is either currently on TRIPLE therapy with a LABA/LAMA/ICS and would benefit from once daily, single inhaler use for improved medication adherence OR failure of adequate treatment with LABA plus LAMA or ICS plus LABA. LABA = long acting beta agonist (ie: formoterol, salmeterol, vilanterol) LAMA = long acting muscarinic agonist (ie: tiotropium, glycopyrronium) ICS = inhaled corticosteroid (ie: fluticasone, budesonide, mometasone, beclometasone)</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
**TRELSTAR DEPOT, TRELSTAR LA**

**Products Affected**
- Trelstar intramuscular suspension for reconstitution

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>DIAGNOSIS</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>PRESCRIPTION MUST BE WRITTEN BY AN ONCOLOGIST.</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>6 MONTHS AT A TIME</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
TRETINOIN

Products Affected
- Avita topical cream
- Avita topical gel
- tretinoin topical

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>Coverage is not provided for cosmetic use.</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>N/A</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 year</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
### TRIENTINE

**Products Affected**
- trientine

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, other therapies tried and the outcome, ferritin, LFTs baseline, serum iron, hemoglobin, and hematocrit</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescribed by or in consultation with a gastroenterologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 months for initiation, 6 months for continuation</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Must have a failure, contraindication, or intolerance to penicillamine.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## Prior Authorization Criteria

**Health Alliance Plan 2020**

**Date Effective:** 02/01/2020

**Formulary ID:** 20495, V#9

### TURALIO

#### Products Affected
- Turalio

#### PA Criteria | Criteria Details
--- | ---
**Exclusion Criteria** | N/A

**Required Medical Information** | Diagnosis: symptomatic tenosynoval giant cell tumor associated with severe morbidity or functional limitations and not amenable to improvement with surgery in adults. Prior therapy used, result of prior therapy. If continuation, prior response to pexidartinib.

**Age Restrictions** | N/A

**Prescriber Restrictions** | Prescribed by or in consultation with an oncologist.

**Coverage Duration** | 3 months initiation and 1 year continuation

**Other Criteria** | N/A

**Indications** | All Medically-accepted Indications.

**Off-Label Uses** | N/A
## TYKERB

### Products Affected
- Tykerb

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>DIAGNOSIS, PRIOR AND CURRENT THERAPIES, TREATMENT RESPONSE</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>18 YEARS AND OLDER</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>PRESCRIPTION MUST BE WRITTEN BY ONCOLOGIST</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
### UCERIS

#### Products Affected
- budesonide oral tablet, delayed and ext. release

<table>
<thead>
<tr>
<th><strong>PA Criteria</strong></th>
<th><strong>Criteria Details</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Exclusion Criteria</strong></td>
<td>Not approved for maintenance of remission or in patients with severe disease (UCDAI score = 10)</td>
</tr>
<tr>
<td><strong>Required Medical Information</strong></td>
<td>Diagnosis, other therapies tried and/or failed, including anti-inflammatory and immunosuppressant drugs</td>
</tr>
<tr>
<td><strong>Age Restrictions</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Prescriber Restrictions</strong></td>
<td>Prescription must be written by a gastroenterology specialist</td>
</tr>
<tr>
<td><strong>Coverage Duration</strong></td>
<td>3 months</td>
</tr>
<tr>
<td><strong>Other Criteria</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td><strong>Off-Label Uses</strong></td>
<td>N/A</td>
</tr>
</tbody>
</table>
# UPTRAVI

## Products Affected
- Uptravi

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Confirmation of diagnosis of PAH, other therapies tried, and documentation of response to therapy</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by a cardiologist or pulmonologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 months for initial, 1 year for continuation</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Must have PAH WHO group 1. Prior to receiving treatment with Uptravi, patient must have a contraindication, intolerance to, or history of taking a PDE5 inhibitor (sildenafil or Adcirca) AND an ERA (bosentan or ambrisentan)</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
### Products Affected
- Ravicti
- sodium phenylbutyrate oral powder

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>N/A</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 months for initiation, 1 year for continuation</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
Prior Authorization Criteria  
Health Alliance Plan 2020  
Date Effective: 02/01/2020  

# VALCHLOR

## Products Affected
- Valchlor

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>N/A</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# VELTASSA

## Products Affected
- Veltassa

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Evidence of episodes of moderate to severe hyperkalemia (serum potassium level = 5.1 mEq/L) requiring discontinuation or dose reduction of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and/or aldosterone antagonists AND receives medication regimen that allows for practical administration of Veltassa 3 hours before or 3 hours after other oral medications</td>
</tr>
</tbody>
</table>

- Age Restrictions    | N/A                                                                                                                                         |
- Prescriber Restrictions | N/A                                                                                                                                           |
- Coverage Duration    | 1 year                                                                                                                                       |
- Other Criteria       | N/A                                                                                                                                         |
- Indications          | All Medically-accepted Indications.                                                                                                           |
- Off-Label Uses       | N/A                                                                                                                                         |
## VENCLEXTA

### Products Affected
- Venclexta
- Venclexta Starting Pack

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis. Other treatments tried and response to therapies.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescribed by or in consultation with a hematologist or oncologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## VERZENIO

### Products Affected
- Verzenio

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>NA</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Documentation of diagnosis, previous treatments, response to treatment, and LFTs.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescribed by oncology</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
**VITRAKVI**

**Products Affected**
- Vitrakvi

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, prior therapies, and result of prior therapy.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by an oncologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## VIZIMPRO

### Products Affected
- Vizimpro

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to treatment.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by an oncologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
**VOTRIENT**

**Products Affected**
- Votrient

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>DIAGNOSIS, OTHER THERAPIES TRIED AND FAILED, RESPONSE TO TREATMENT</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>PRESCRIPTION MUST BE WRITTEN BY AN ONCOLOGIST</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
XATMEP

Products Affected
- Xatmep

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, prior treatments, response to therapy</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by an oncologist or rheumatologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Medical justification as to why member cannot use methotrexate tablets or injectable solution</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## XELJANZ

### Products Affected
- Xeljanz
- Xeljanz XR

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, prior therapy used, response to prior therapy. Documentation of negative TB test.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>PRESCRIPTION MUST BE WRITTEN BY A SPECIALIST (INCLUDING BUT NOT LIMITED TO RHEUMATOLOGIST OR GASTROENTEROLOGIST)</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 months for initiation, 2 years for continuation</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Prior to receiving treatment with Xeljanz for arthritis related condition, patient must have trial of or contraindication to at least one non-biologic DMARD (including but not limited to methotrexate, hydroxychloroquine, sulfasalazine, azathioprine). Dose adjustments and laboratory monitoring parameters should be adhered to as specified in the FDA approved drug labeling.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## Prior Authorization Criteria

**Health Alliance Plan 2020**

**Date Effective:** 02/01/2020

### XENAZINE

#### Products Affected
- tetrabenazine

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Exclusion Criteria</strong></td>
<td>CONTRAINDICATED IN PATIENTS WITH HEPATIC DISEASE, THOSE TAKING MAOIS, OR WITH UNTREATED OR INADEQUATELY TREATED DEPRESSION</td>
</tr>
<tr>
<td><strong>Required Medical Information</strong></td>
<td>DIAGNOSIS OF HUNTINGTONS DISEASE</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>PRESCRIPTION MUST BE WRITTEN BY NEUROLOGIST</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 YEAR</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>CYP2D6 GENOTYPING IS REQUIRED FOR PATIENTS WHO REQUIRE MORE THAN 50 MG PER DAY</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
**XERMELO**

**Products Affected**
- Xermelo

<table>
<thead>
<tr>
<th><strong>PA Criteria</strong></th>
<th><strong>Criteria Details</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Exclusion Criteria</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Required Medical Information</strong></td>
<td>Diagnosis of carcinoid syndrome diarrhea AND diarrhea is inadequately controlled by a stable dose of somatostatin analog (SSA) therapy (e.g., octreotide, Somatuline Depot) for at least 3 months AND used in combination with SSA therapy.</td>
</tr>
<tr>
<td><strong>Age Restrictions</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Prescriber Restrictions</strong></td>
<td>Prescribed by or in consultation with an oncologist, endocrinologist, or gastroenterologist</td>
</tr>
<tr>
<td><strong>Coverage Duration</strong></td>
<td>2 years</td>
</tr>
<tr>
<td><strong>Other Criteria</strong></td>
<td>For continuation of therapy-Documentation of a positive clinical response to Xermelo therapy AND Xermelo will continue to be used in combination with SSA therapy.</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td><strong>Off-Label Uses</strong></td>
<td>N/A</td>
</tr>
</tbody>
</table>

Formulary ID 20495, V#9
## Prior Authorization Criteria

**Health Alliance Plan 2020**  
Date Effective: 02/01/2020

---

### XGEVA

#### Products Affected
- Xgeva

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, other therapies tried and/or failed</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by oncologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 year</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# XIFAXAN

## Products Affected
- Xifaxan

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>Not covered for prophylaxis for travelers diarrhea or small bowel overgrowth (SIBO).</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Confirmation of diagnosis, documentation of response to any prior therapies</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 months for travelers diarrhea (TD) and recurrent C. diff.  1 year for all other conditions</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>For hepatic encephalopathy: treatment failure, intolerance, or contraindication to lactulose. For travelers diarrhea: treatment failure, intolerance, or contraindication to a fluoroquinolone (such as ciprofloxacin) and azithromycin. For IBS-D: treatment failure, intolerance, or contraindication to loperamide and dicyclomine. For recurrent C. difficile: treatment failure, intolerance, or contraindication to vancomycin.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
Prior Authorization Criteria
Health Alliance Plan 2020
Date Effective: 02/01/2020

**XIIDRA**

**Products Affected**
- Xiidra

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis and other therapies tried.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>Initial, reauth: 12 months</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Failure, contraindication, or intolerance to Restasis at an optimal dose and frequency for at least 2 weeks</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# XOLAIR

## Products Affected
- Xolair

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>weight above 330 lbs</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>For asthma: weight, IgE level at baseline, baseline FEV1, FEV1 following bronchodilator, medication history, ER visits, and hospitalizations. Evidence of a positive skin test or in-vitro reactivity to a perennial aeroallergen. For urticaria: documentation of persistence of hives associated with itching and prior treatments with outcome.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>pulmonologist, immunologist, allergist, or dermatologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>1 year</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>For asthma: IgE serum concentration between 30-700 IU/ml for adults and 30-1,300 IU/mL for children, concurrent therapy with inhaled corticosteroids and long-acting -agonists for ≥3 months duration, and evidence of oral steroids or ER visits/hospitalizations. For urticaria: failure, intolerance, or contraindication to desloratadine and montelukast.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# XOSPATA

## Products Affected
- Xospata

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, prior therapies, and result of prior therapy.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by an oncologist or hematologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## XPOVIO

### Products Affected
- Xpovio

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical</td>
<td>Diagnosis, other therapies tried and/or failed, and treatment response. Used in</td>
</tr>
<tr>
<td>Information</td>
<td>combination with dexamethasone.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by an oncologist or hematologist.</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 months for initial authorization, 12 months for continuation.</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Must demonstrate treatment with at least 4 prior therapies and whose disease is</td>
</tr>
<tr>
<td></td>
<td>refractory to at least 2 proteasome inhibitors, at least 2 immunomodulatory</td>
</tr>
<tr>
<td></td>
<td>agents, and an anti-CD38 monoclonal antibody.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
# XTANDI

## Products Affected
- Xtandi

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to enzalutamide.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by an oncologist or urologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Patient must undergo evaluation of seizure risk. For metastatic castration resistant prostate cancer (CRPC), patient must have a failure, intolerance, or contraindication to Zytiga prior to initiation of therapy with Xtandi.</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
XURIDEN

Products Affected
- Xuriden

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>The starting dose will be approved for 60 mg/kg once daily. Higher doses will be approved (up to 120 mg/kg once daily) in the following situations: Levels of orotic acid in urine remain above normal or increase above the usual or expected range for the patient OR Laboratory values (e.g., red blood cell or white blood cell indices) affected by hereditary orotic aciduria show evidence of worsening OR Worsening of other signs or symptoms of the disease</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 months initial, 1 year continuation</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
## XYREM

### Products Affected
- Xyrem

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>Not to be used in patients concurrently using alcohol or sedative-hypnotic agents</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, other therapies tried and failed</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by a sleep medicine specialist or neurologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>3 months for initiation, 6 months for continuation</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>Dosing approved up to 9 grams per day</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
### ZEJULA

#### Products Affected
- Zejula

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Documentation of diagnosis, prior therapies, and response to therapy</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescribed by or in consultation with an oncologist, endocrinologist, or gastroenterologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Formulary ID 20495, V#9
Prior Authorization Criteria
Health Alliance Plan 2020
Date Effective: 02/01/2020

ZELBORAF

Products Affected
- Zelboraf

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Exclusion Criteria</strong></td>
<td>PATIENTS WITH WILD-TYPE BRAF MELANOMA, PREGNANCY</td>
</tr>
<tr>
<td><strong>Required Medical Information</strong></td>
<td>FOR METASTATIC MELANOMA: DOCUMENTATION OF DIAGNOSIS AND BRAF V600E MUTATION AS DETECTED USING AN FDA-APPROVED TEST. FOR ERDHEIM-CHESTER DISEASE: DOCUMENTATION OF DIAGNOSIS AND BRAF V600 MUTATION.</td>
</tr>
<tr>
<td><strong>Age Restrictions</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Prescriber Restrictions</strong></td>
<td>PRESCRIPTION MUST BE WRITTEN BY AN ONCOLOGIST.</td>
</tr>
<tr>
<td><strong>Coverage Duration</strong></td>
<td>2 years</td>
</tr>
<tr>
<td><strong>Other Criteria</strong></td>
<td>PERFORM DERMATOLOGICAL EVALUATIONS PRIOR TO INITIATION OF THERAPY AND EVERY 2 MONTHS WHILE ON THERAPY TO MONITOR FOR NEW PRIMARY MELANOMAS. MONITOR LIVER FUNCTION TESTS PRIOR TO INITIATION OF THERAPY AND AS CLINICALLY INDICATED THEREAFTER. MONITOR ECGs PRIOR TO INITIATION OF THERAPY, AT DAY 15, THEN MONTHLY, AND EVERY 3 MONTHS THEREAFTER. MONITOR PATIENTS FOR OPHTHALMOLOGIC REACTIONS AS CLINICALLY INDICATED.</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td><strong>Off-Label Uses</strong></td>
<td>N/A</td>
</tr>
</tbody>
</table>
## ZYDELG

### Products Affected

- Zydelig

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical</td>
<td>DIAGNOSIS, PRIOR TREATMENTS, RESPONSE TO THERAPY. FOR PATIENTS WITH CLL OR SLL,</td>
</tr>
<tr>
<td>Information</td>
<td>DOCUMENTATION OF PRIOR TREATMENT WITH IMBRUVICA. IF NO PREVIOUS FAILURE, RATIONALE</td>
</tr>
<tr>
<td></td>
<td>AS TO WHY PREFERRED AGENT CANNOT BE USED</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>PRESCRIPTION MUST BE WRITTEN BY ONCOLOGIST OR HEMATOLOGIST</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Formulary ID 20495, V#9
# ZYTIGA

## Products Affected
- abiraterone
- Zytiga oral tablet 500 mg

<table>
<thead>
<tr>
<th>PA Criteria</th>
<th>Criteria Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Required Medical Information</td>
<td>Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to abiraterone.</td>
</tr>
<tr>
<td>Age Restrictions</td>
<td>N/A</td>
</tr>
<tr>
<td>Prescriber Restrictions</td>
<td>Prescription must be written by an oncologist or urologist</td>
</tr>
<tr>
<td>Coverage Duration</td>
<td>2 years</td>
</tr>
<tr>
<td>Other Criteria</td>
<td>N/A</td>
</tr>
<tr>
<td>Indications</td>
<td>All Medically-accepted Indications.</td>
</tr>
<tr>
<td>Off-Label Uses</td>
<td>N/A</td>
</tr>
</tbody>
</table>
PART B VERSUS PART D

Products Affected
- Abelcet
- acetylcysteine
- acyclovir sodium intravenous solution
- albuterol sulfate inhalation solution for nebulization 0.63 mg/3 mL, 1.25 mg/3 mL, 2.5 mg /3 mL (0.083 %), 2.5 mg/0.5 mL
- AmBisome
- Aminosyn II 10 %
- Aminosyn II 15 %
- Aminosyn-PF 10 %
- Aminosyn-PF 7 % (sulfite-free)
- amphotericin B
- Astagraf XL
- Azasan
- azathioprine
- Bethkis
- Brovana
- budesonide inhalation
- Clinimix 5%/D15W Sulfite Free
- Clinimix 4.25%/D10W Sulf Free
- Clinimix 4.25%/D5W Sulfite Free
- Clinimix 5%-D20W(sulfite-free)
- Clinimix E 2.75%/D5W Sulf Free
- Clinimix E 4.25%/D10W Sul Free
- Clinimix E 4.25%/D5W Sulf Free
- Clinimix E 5%/D15W Sulf Free
- Clinimix E 5%/D20W Sulfite Free
- Clinisol SF 15 %
- cromolyn inhalation
- cyclophosphamide oral capsule
- cyclosporine modified
- cyclosporine oral capsule
- dexamethasone oral elixir
- dexamethasone oral tablet
- dexamethasone vial
- Engerix-B (PF) intramuscular syringe
- Engerix-B Pediatric (PF) intramuscular syringe
- Freamine HBC 6.9 %
- Gengraf oral capsule 100 mg, 25 mg
- Gengraf oral solution
- granisetron HCl oral
- Hepatamine 8 %
- Imovax Rabies Vaccine (PF)
- Intralipid intravenous emulsion 30 %
- ipratropium bromide inhalation
- ipratropium-albuterol
- levalbuterol HCl
- methylprednisolone oral tablet
- Millipred oral tablet
- mycophenolate mofetil
- mycophenolate sodium
- Myfortic
- Nebupent
- Neoral
- Nephramine 5.4 %
- ondansetron
- ondansetron HCl oral
- Perforomist
- Plenamine
- prednisolone oral solution 15 mg/5 mL
- prednisolone sodium phosphate oral solution 10 mg/5 mL, 20 mg/5 mL (4 mg/mL), 25 mg/5 mL (5 mg/mL), 5 mg base/5 mL (6.7 mg/5 mL)
- Prednisone Intensol
- prednisone oral solution
- prednisone oral tablet
- Premasol 10 %
- Premasol 6 %
- Procalamine 3 %
- Prograf oral granules in packet
- Pulmozyme
- RabAvert (PF)
- Rapamune
- Recombivax HB (PF) intramuscular suspension 10 mcg/mL, 40 mcg/mL
- Recombivax HB (PF) intramuscular syringe
- Sandimmune oral
- sirolimus
Prior Authorization Criteria
Health Alliance Plan 2020
Date Effective: 02/01/2020

- tacrolimus oral
- tobramycin in 0.225 % NaCl
- Travasol 10 %
- TrophAmine 10 %
- Veripred
- Yupelri
- Zortress

Details
This drug may be covered under Medicare Part B or D depending upon the circumstances. Information may need to be submitted describing the use and setting of the drug to make the determination.
## Index

<table>
<thead>
<tr>
<th>A</th>
<th>Astagraf XL ........................................ 207</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abelcet</td>
<td>Aubagio................................................ 101</td>
</tr>
<tr>
<td>Abilify Maintena .................................. 11</td>
<td></td>
</tr>
<tr>
<td>abiraterone ........................................ 206</td>
<td></td>
</tr>
<tr>
<td>acetylcysteine ...................................... 207</td>
<td></td>
</tr>
<tr>
<td>acitretin ............................................ 149</td>
<td></td>
</tr>
<tr>
<td>acyclovir sodium intravenous solution ............. 207</td>
<td></td>
</tr>
<tr>
<td>adapalene topical cream ................................2</td>
<td></td>
</tr>
<tr>
<td>adpalene topical gel 0.1% ................................2</td>
<td></td>
</tr>
<tr>
<td>adpalene topical swab ..................................2</td>
<td></td>
</tr>
<tr>
<td>Adempas ..................................................3</td>
<td></td>
</tr>
<tr>
<td>Afinitor ..................................................4</td>
<td></td>
</tr>
<tr>
<td>Afinitor Disperz .......................................4</td>
<td></td>
</tr>
<tr>
<td>Aimovig Autoinjector ...................................5</td>
<td></td>
</tr>
<tr>
<td>albuterol sulfate inhalation solution for nebulization 0.63 mg/3 mL, 1.25 mg/3 mL, 2.5 mg/3 mL (0.083 %), 2.5 mg/0.5 mL ................................................................. 207</td>
<td></td>
</tr>
<tr>
<td>Alecensa ...................................................6</td>
<td></td>
</tr>
<tr>
<td>Alunbrig ...................................................7</td>
<td></td>
</tr>
<tr>
<td>Alyq ..................................................................126</td>
<td></td>
</tr>
<tr>
<td>AmBisome .....................................................207</td>
<td></td>
</tr>
<tr>
<td>ambrisentan .................................................134</td>
<td></td>
</tr>
<tr>
<td>Aminosyn II 10% .......................................... 207</td>
<td></td>
</tr>
<tr>
<td>Aminosyn II 15% .......................................... 207</td>
<td></td>
</tr>
<tr>
<td>Aminosyn-PF 10% ......................................... 207</td>
<td></td>
</tr>
<tr>
<td>Aminosyn-PF 7% (sulfite-free) .......................... 207</td>
<td></td>
</tr>
<tr>
<td>amphotericin B .............................................207</td>
<td></td>
</tr>
<tr>
<td>Ampyra ........................................................ 9</td>
<td></td>
</tr>
<tr>
<td>APOKYN .......................................................12</td>
<td></td>
</tr>
<tr>
<td>aprepitant ....................................................34</td>
<td></td>
</tr>
<tr>
<td>Aralast NP intravenous recon soln 1,000 mg .............1</td>
<td></td>
</tr>
<tr>
<td>Aranesp (in polysorbate) injection solution 100 mcg/mL, 200 mcg/mL, 25 mcg/mL, 300 mcg/mL, 40 mcg/mL, 60 mcg/mL 40, 41</td>
<td></td>
</tr>
<tr>
<td>Aranesp (in polysorbate) injection syringe ..............40, 41</td>
<td></td>
</tr>
<tr>
<td>Arcalyst ......................................................13</td>
<td></td>
</tr>
<tr>
<td>Aristada .......................................................11</td>
<td></td>
</tr>
<tr>
<td>Aristada Initio .............................................11</td>
<td></td>
</tr>
<tr>
<td>Azasan ..........................................................207</td>
<td></td>
</tr>
<tr>
<td>azathioprine .................................................207</td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>Braftovi oral capsule 75 mg ................................17</td>
</tr>
<tr>
<td>Balversa .....................................................14</td>
<td></td>
</tr>
<tr>
<td>Baraclude oral solution ..................................55</td>
<td></td>
</tr>
<tr>
<td>Benlysta subcutaneous syringe ......................... 15</td>
<td></td>
</tr>
<tr>
<td>Betaseron subcutaneous kit ..............................101</td>
<td></td>
</tr>
<tr>
<td>Bethkis ........................................................ 207</td>
<td></td>
</tr>
<tr>
<td>bosentan .....................................................134</td>
<td></td>
</tr>
<tr>
<td>Bosulif oral tablet 100 mg, 400 mg, 500 mg ..............16</td>
<td></td>
</tr>
<tr>
<td>budesonide inhalation .................................... 207</td>
<td></td>
</tr>
<tr>
<td>budesonide oral tablet,delayed and ext.release ........ 180</td>
<td></td>
</tr>
<tr>
<td>C</td>
<td>Cabometyx ..................................................18</td>
</tr>
<tr>
<td>Calquence ...................................................19</td>
<td></td>
</tr>
<tr>
<td>Caprelsa oral tablet 100 mg, 300 mg .. 20, 21</td>
<td></td>
</tr>
<tr>
<td>Cerdelga .....................................................50</td>
<td></td>
</tr>
<tr>
<td>Cinqair ........................................................ 21</td>
<td></td>
</tr>
<tr>
<td>Cinryze ........................................................ 57</td>
<td></td>
</tr>
<tr>
<td>Clinimix 5%/D15W Sulfite Free .......................... 207</td>
<td></td>
</tr>
<tr>
<td>Clinimix 4.25%/D10W Sulf Free .......................... 207</td>
<td></td>
</tr>
<tr>
<td>Clinimix 4.25%/D5W Sulfit Free .......................... 207</td>
<td></td>
</tr>
<tr>
<td>Clinimix 5%-D20W(sulfite-free) ......................... 207</td>
<td></td>
</tr>
<tr>
<td>Clinimix E 2.75%/D5W Sulf Free .......................... 207</td>
<td></td>
</tr>
<tr>
<td>Clinimix E 4.25%/D10W Sul Free .......................... 207</td>
<td></td>
</tr>
<tr>
<td>Clinimix E 4.25%/D5W Sulf Free .......................... 207</td>
<td></td>
</tr>
<tr>
<td>Clinimix E 5%/D15W Sulfit Free .......................... 207</td>
<td></td>
</tr>
<tr>
<td>Clinimix E 5%/D20W Sulfit Free .......................... 207</td>
<td></td>
</tr>
<tr>
<td>Clinisol SF 15% .............................................207</td>
<td></td>
</tr>
<tr>
<td>Cometriq .......................................................22</td>
<td></td>
</tr>
<tr>
<td>Copiktra .......................................................23</td>
<td></td>
</tr>
</tbody>
</table>
Prior Authorization Criteria
Health Alliance Plan 2020
Date Effective: 02/01/2020

Corlanor .............................................. 24
Cosentyx (2 Syringes).............................. 25
Cosentyx Pen (2 Pens) ............................. 25
Cotellic .............................................. 26
cromolyn inhalation ................................ 207
cyclophosphamide oral capsule ............... 207
cyclosporine modified ............................ 207
cyclosporine oral capsule ....................... 207
D
Daliresp .............................................. 27
Daurismo ............................................. 28
deferasirox oral tablet, dispersible ............ 42
Demser .............................................. 29
dexamethasone oral elixir ........................ 207
dexamethasone oral tablet ....................... 207
diclofenac sodium topical gel 3 % ....... 30
Doptelet (10 tab pack) ............................ 31
Doptelet (15 tab pack) ............................ 31
Doptelet (30 tab pack) ............................ 31
Drizalma Sprinkle ................................. 10
dronabinol .......................................... 32
E
Egrifta subcutaneous recon soln 1 mg ..... 33
Enbrel ................................................ 35, 36
Enbrel SureClick .................................. 35, 36
Engerix-B (PF) intramuscular syringe .... 207
Engerix-B Pediatric (PF) intramuscular syringe ........................................... 207
entecavir ............................................. 55
Epidiolex ............................................. 37
Epogen injection solution 2,000 unit/mL, 20,000 unit/2 mL, 20,000 unit/mL, 3,000 unit/mL, 4,000 unit/mL .................. 40, 41
Erivedge ............................................ 38
Erleada .............................................. 39
erlotinib ............................................. 164
Esbriet .............................................. 133
Exjade .............................................. 42
F
Fanapt ................................................. 11
Farydak ............................................. 43
Fasenra ............................................. 44
Fasenra Pen ......................................... 44
fentanyl citrate buccal lozenge on a handle .................................................. 173
Ferriprox oral tablet .............................. 45
Fetzima ............................................. 10
Firdapse ............................................. 8
Flebogamma DIF intravenous solution 10 % ............................................. 74
Flebogamma DIF intravenous solution 10 % (10 %) ............................................. 74
Flebogamma (with sorbitol) .................. 74
Gamunex-C injection solution 1 gram/10 mL (10 %) ............................................. 74
Gattex 30-Vial ..................................... 49
Gengraf oral capsule 100 mg, 25 mg ..... 207
Gengraf oral solution ............................ 207
Gilenya oral capsule 0.5 mg ..................... 101
Gilotrif .............................................. 51
Glassia ............................................. 1
glatiramer ........................................... 101
Glatopa .............................................. 101
Gralise ............................................. 53
Gralise 30-Day Starter Pack .................. 53
granisetron HCl oral ............................. 207
guanfacine oral tablet extended release 24 hr ............................................... 72
H
Haegarda ............................................ 57
Hepatamine 8% ................................... 207
Hetlioz ............................................ 58
Humira ............................................. 60, 61
Humira Pediatric Crohns Start ............... 60, 61
Humira Pen ......................................... 60, 61
Humira Pen Crohns-UC-HS Start ........... 60, 61
Humira Pen Psor-Uveits-Adol HS ......... 60, 61
Humira(CF) ........................................ 60, 61
Humira(CF) Pedi Crohns Starter .......... 60, 61
Humira(CF) Pen Crohns-UC-HS ............ 60, 61
Humira(CF) Pen Psor-Uv-Adol HS ....... 60, 61
Prior Authorization Criteria
Health Alliance Plan 2020
Date Effective: 02/01/2020

Humira (CF) Pen subcutaneous pen injector
kit 40 mg/0.4 mL .................................. 60, 61
I
Ibrance .............................................. 62
Icatibant ......................................... 57
Iclusig ............................................. 63
Idhifa ............................................. 64
Imatinib .......................................... 52
Imbruvica oral capsule 140 mg, 70 mg .... 65
Imbruvica oral tablet .................................. 65
Imovax Rabies Vaccine (PF) ............... 207
Inbria inhalation capsule, w/inhalation
device ............................................. 66
Increlex ......................................... 67
Inlyta oral tablet 1 mg, 5 mg ................. 69
Inrebic ........................................... 70
Intralipid intravenous emulsion 30 % .... 207
Intron A injection................................ 71
Invega Sustenna .................................. 11
Invega Trinza ...................................... 11
Ipratropium bromide inhalation ........... 207
Ipratropium-albuterol ......................... 207
Iressa .................................................. 73
J
Jakafi ............................................... 75
Juxtapid .......................................... 59
Jynarque oral tablets, sequential ............ 76
K
Kalydeco ......................................... 77
Kineret ........................................... 78
Kisqali ............................................ 79
Kisqali Femara Co-Pack ...................... 79
Korlym ........................................... 80
Kuvan oral powder in packet 100 mg ...... 81
Kuvan oral tablet, soluble ...................... 81
L
Latuda ............................................. 11
Lazanda .......................................... 173
Lenvima .......................................... 82
Letairis .......................................... 134
Leukine injection recon soln .................. 83
Levalbuterol HCl ................................ 207
Libtayo ........................................... 84
Lidocaine topical adhesive patch, medicated
.................................................. 84
lidocaine topical adhesive patch, medicated
.................................................. 85
lidocaine topical ointment ................. 84, 85
Linzess ........................................... 86
Lokelma ......................................... 87
Lonsurf .......................................... 88
Lorbrena ........................................ 89
Lynparza oral tablet ......................... 90
M
Mavenclad (10 tablet pack) ............... 91
Mavenclad (4 tablet pack) ................. 91
Mavenclad (5 tablet pack) ................. 91
Mavenclad (6 tablet pack) ................. 91
Mavenclad (7 tablet pack) ................. 91
Mavenclad (8 tablet pack) ................. 91
Mavenclad (9 tablet pack) ................. 91
Mavyret ........................................... 56
Mayzent ......................................... 92
Megestrol oral suspension 400 mg/10 mL
(40 mg/mL), 625 mg/5 mL ............. 93
Megestrol oral tablet ......................... 93
Mekinist oral tablet 0.5 mg, 2 mg ....... 94
Mektovi ......................................... 95
Methadone oral solution ..................... 96
Methadone oral tablet ....................... 96
Methamphetamine ................................ 97
Methylprednisolone oral tablet ............. 207
Miglustat ........................................ 50
Millipred oral tablet ......................... 207
Mirvaso topical gel with pump .......... 98
Modafinil ........................................ 132
Movantin ........................................ 99
Mulpleta .......................................... 100
Myalept ........................................... 102
Mycophenolate mofetil ....................... 207
Mycophenolate sodium ...................... 207
Myfortic .......................................... 207
Mytesi ........................................... 46
N
Natpara ........................................... 103
Nayzilam ......................................... 104
Nebupent ......................................... 207
Neoral ............................................ 207
Nerlynx .......................................... 105
Prior Authorization Criteria
Health Alliance Plan 2020
Date Effective: 02/01/2020

Neupro................................................. 106
Nexavar............................................... 107
Ninlaro............................................... 108
Norditropin FlexPro......................... 54
Noxfal oral suspension..................... 109
Nubeqa................................................. 110
Nucala................................................. 111
Nuedexta............................................. 112
Nuplazid oral capsule....................... 113
Nuplazid oral tablet 10 mg............... 113
Nutropin AQ Nuspip......................... 54
Ocaliva............................................... 114
Octagam............................................. 74
Octreotide acetate injection solution.... 115
Odomzo............................................... 116
Ofev.................................................. 133
ondansetron...................................... 207
ondansetron HCl oral....................... 207
Opsumit............................................. 134
Orencia.............................................. 117
Orencia ClickJect............................ 117
Orfadin............................................. 118
Orilissa............................................. 120
Orkambi oral granules in packet........ 119
Orkambi oral tablet......................... 119
Otezla............................................... 121
Otezla Starter oral tablets,dose pack 10 mg
(4)-20 mg (4)-30 mg (47)............... 121
Oxervate............................................. 122
oxycodone oral tablet,oral only,ext.rel.12 hr
.................................................. 123
P
Palynziq............................................ 124
Panretin............................................. 125
Pegasys............................................. 71
Pegasys ProClick subcutaneous pen injector
180 mcg/0.5 mL.............................. 71
Perforomist........................................ 207
Piqray............................................... 127
Plegridy............................................. 101
Plenamine.......................................... 207
Pomalyst........................................... 128
prednisolone oral solution 15 mg/5 mL.. 207
predicted sodium phosphate oral solution
10 mg/5 mL, 20 mg/5 mL (4 mg/mL), 25
mg/5 mL (5 mg/mL), 5 mg base/5 mL
(6.7 mg/5 mL)................................. 207
Prednisone Intensol......................... 207
prednisone oral solution.................... 207
prednisone oral tablet...................... 207
Premasol 10 %................................. 207
Premasol 6 %................................. 207
Privigen............................................ 74
Procalamine 3%.............................. 207
Procrit injection solution 10,000 unit/mL,
2,000 unit/mL, 20,000 unit/mL, 3,000
unit/mL, 4,000 unit/mL, 40,000 unit/mL
.................................................. 40, 41
Prograf oral granules in packet........... 207
Prolastin-C intravenous recon soln........ 1
Prolia.............................................. 129, 130
Promacta.......................................... 131
Pulmozyme....................................... 207
Purixan............................................ 135
R
RabAvert (PF).................................. 207
Rapamune........................................ 207
Ravicti............................................ 182
Recombivax HB (PF) intramuscular
suspension 10 mcg/mL, 40 mcg/mL.... 207
Recombivax HB (PF) intramuscular syringe
.................................................. 207
Relistor oral................................. 136, 138
Relistor subcutaneous solution ....... 136, 138
Relistor subcutaneous syringe......... 136, 138
Repatha......................................... 137
Repatha Pushtronex...................... 137
Repatha SureClick....................... 137
Revvuci.......................................... 138
Revlid.............................................. 139
Rexulti............................................ 11
Rinvoq ER...................................... 140
Rozlytrek oral capsule 100 mg, 200 mg.. 141
Rubraca......................................... 142
Ruzurgi............................................ 8
Rydapt.......................................... 143
S
Samsca......................................... 144
Prior Authorization Criteria
Health Alliance Plan 2020
Date Effective: 02/01/2020

Sandimmune oral .................................. 207
Saphris ............................................. 11
Savella oral tablet .................................. 145
Savella oral tablets, dose pack .............. 145
Signifor ............................................. 146
tadalafil (Pulmonary Arterial Hypertension) oral .......... 126, 134
sirolimus ........................................... 207
Sirturo ............................................. 147
Skyrizi subcutaneous syringe kit .............. 148
sodium phenylbutyrate oral powder ....... 182
Spritan ............................................ 150
Sprycel ............................................ 151
Stelara subcutaneous ......................... 152
Stivarga .......................................... 153
Sutent ............................................. 154
Sylatron .......................................... 155
Symdeko ......................................... 156
SymlinPen 120 .................................. 157
SymlinPen 60 .................................... 157
Sympazan oral film 10 mg, 20 mg, 5 mg 158
Synribo ............................................ 159
tacrolimus oral .................................. 208
tadalafil (pulm. hypertension) ............... 126
Tafinlar .......................................... 161
Tagrisso .......................................... 162
Takhzyro .......................................... 57
Talzenna ......................................... 163
Targretin ......................................... 164
Tasigna oral capsule 150 mg, 200 mg, 50 mg .................. 165
Tavalisse ......................................... 166
tazarotene ....................................... 167
Tazosert ............................................ 167
Tecfidera .......................................... 101
Tegsedi ............................................ 168
Tekturna .......................................... 169
Tekturna HCT .................................... 169
testosterone transdermal gel in metered-dose pump 12.5 mg/1.25 gram (1%), 20.25 mg/1.25 gram (1.62%) .......... 170, 171
testosterone transdermal gel in packet .... 170, 171
tetrahydrozoline .................................. 192
Tibsovo ............................................ 172
tobramycin in 0.225 % NaCl ..................... 208
topiramate oral capsule, sprinkle ............ 93
topiramate oral tablet ......................... 93
Tracleer .......................................... 134
Travasol 10 % ................................... 208
Trelstar Ellipta .................................... 174
tretinoin topical .................................. 176
trientine .......................................... 177
Trientilix .......................................... 10
Trofast 200 mg .................................. 208
Turalio ............................................. 178
Tykerb ............................................ 179
Uptravi ............................................ 181
Valchlor .......................................... 183
Veltassa .......................................... 184
Venclexa ......................................... 185
Venclexa Starting Pack ......................... 185
Ventavis .......................................... 134
Versacloz .......................................... 11
Verzenio .......................................... 186
Viibryd oral tablet ................................ 10
Viibryd oral tablets, dose pack 10 mg (7)- 20 mg (23) ......................... 10
Vitrakvi ........................................... 187
Vizimpro .......................................... 188
Votrient .......................................... 189
Vraylar ............................................ 11
Vyndamax ........................................ 160
Vyndaqel ........................................ 160
Xalkori ........................................... 6
Xatmep .......................................... 190
Xeljanz ........................................... 191
Xeljanz XR ........................................ 191
Xermelos ......................................... 193
Xgeva ............................................ 194
Xifaxan .......................................... 195
Prior Authorization Criteria  
Health Alliance Plan 2020  
Date Effective: 02/01/2020

<table>
<thead>
<tr>
<th>Drug</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xiidra</td>
<td>196</td>
</tr>
<tr>
<td>Xolair</td>
<td>197</td>
</tr>
<tr>
<td>Xospata</td>
<td>198</td>
</tr>
<tr>
<td>Xprowad</td>
<td>199</td>
</tr>
<tr>
<td>Xtandi</td>
<td>200</td>
</tr>
<tr>
<td>Xuriden</td>
<td>201</td>
</tr>
<tr>
<td>Xyrem</td>
<td>202</td>
</tr>
<tr>
<td>Yupelri</td>
<td>208</td>
</tr>
<tr>
<td>Zavesca</td>
<td>50</td>
</tr>
<tr>
<td>Zejula</td>
<td>203</td>
</tr>
<tr>
<td>Zelboraf</td>
<td>204</td>
</tr>
<tr>
<td>Zemaira</td>
<td>1</td>
</tr>
<tr>
<td>Zepatier</td>
<td>56</td>
</tr>
<tr>
<td>Zonisamide</td>
<td>93</td>
</tr>
<tr>
<td>Zortress</td>
<td>208</td>
</tr>
<tr>
<td>Zydela</td>
<td>205</td>
</tr>
<tr>
<td>Zykadia oral tablet</td>
<td>6</td>
</tr>
<tr>
<td>Zytiga oral tablet 500 mg</td>
<td>206</td>
</tr>
</tbody>
</table>